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Abbreviations 
4T1      mammary carcinoma cell line 
AIM2      absent in melanoma 2 
Arg-1      arginase-1 
ASC apoptosis-associated speck-like protein 
containing a CARD 
ATP      adenosine triphosphate 
BrdU      5-Bromdesoxyuridin 
BSA      bovine serum albumin 
CAR      chimeric antigen receptor 
CARD caspase activation and recruitment 
domain 
CD4+      CD4-positive 
CD8+      CD8-positive 
CTLA-4 cytotoxic T lymphocyte-associated 
protein-4 
DAMPs     damage-associated molecular patterns 
DNA      deoxyribonucleic acid 
ds      double-stranded 
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ECM      extracellular matrix 
ESL-1      E-selectin ligand-1 
FDA      Food and Drug Administration 
FLA-ST     flagellin 
G-CSF     granulocyte-colony stimulating factor  
HER-2 human epidermal growth factor receptor-
2 
HMGB1     high-mobility group box 1 
HNSCC     head and neck squamous cell carcinoma 
HPV      human papillomavirus 
IL      interleukin 
IRS-1      insulin receptor substrate-1 
i.p.       intraperitoneal 
i.s.       intrascrotal 
i.v.       intravenous 
IVM       intravital / in vivo microscopy  
LPS      lipopolysaccharides 
LRR      leucine-rich repeat 
mAb      monoclonal antibody 
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M. cremaster     musculus cremaster  
MDP      muramyl dipeptide  
MHC      major histocompatibility complex 
MMP9      matrix metallopeptidase 9 
MSU      monosodium urate 
NE      neutrophil elastase 
NETs      neutrophil extracellular traps 
NF-κB nuclear factor 'kappa-light-chain-
enhancer' of activated B cells 
NLR      NOD-like receptor 
NLRP1     NLR family pyrin domain-containing 1 
NLRP3     NLR family pyrin domain-containing 3 
NLRC4 NLR family CARD domain-containing 
protein 4 
NOD nucleotide-binding oligomerization 
domain 
PAMPs     pathogen-associated molecular patterns 
PD-1      programmed cell death protein-1 
PI3K       phosphoinositol-3-kinase  
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PMA       phorbol-12-myristat-13-acetat  
PBS       phosphate buffered saline 
PRR      pattern recognition receptor 
PSGL-1     P-selectin glycoprotein ligand-1   
RLR retinoic acid inducible gene-1 like 
receptor 
ROS      reactive oxygen species 
SCC VII     squamous cell carcinoma VII cell line  
SEM       standard error of the mean  
ss       single-stranded  
TGF-β      transforming growth factor-beta  
TH      T-helper cells 
TNF      tumor necrosis factor  
Treg      regulatory T cell 
TLR      toll-like receptor 
VEGF      vascular endothelial growth factor  
WHO      World Health Organization 
WT       wildtype  
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Abstract 
Neutrophils have always been recognized as key players in the acute 
inflammatory response. Their contribution to the pathogenesis of malignant 
tumors, however, is an emerging concept. Recent findings revealed that 
neutrophils undergo phenotypic changes during their time in the circulation, a 
process referred to as biological ageing. Whereas these changes have been 
shown to be crucial for their anti-infectious functions, studies also revealed these 
highly reactive immune cells can oppose a threat to the vascular health. The role 
of neutrophil biological ageing in cancer, however, remains unknown. In the 
present study, we now demonstrate that due to specific chemokines released 
during early tumorigenesis, biological ageing of circulating neutrophils is further 
accelerated, allowing these innate immune cells to accumulate in malignant 
lesions. This is facilitated by DAMPs derived from the tumor, which activate the 
NLRP3 inflammasome in peritumoral macrophages and, in turn, microvascular 
endothelial cells, ultimately facilitating the recruitment of neutrophils to the 
malignancies. Once present in the neoplastic lesions, neutrophils supported tumor 
progression by stimulating tumor cell proliferation through release of neutrophil 
elastase. Counteracting neutrophil ageing (via blockade of the chemokine receptor 
CXCR2) or neutrophil recruitment to the tumor (via inhibition of NLRP3 
inflammasome activation) in tumor-bearing mice severely compromised tumor 
growth. In conclusion, our data uncover a self-sustaining mechanism of malignant 
tumors that induces excessive biological ageing of circulating neutrophils and 
thereby promotes the progression of these neoplastic lesions. This process 
represents a particularly promising therapeutic target as first clinical studies 
already revealed encouraging results of using CXCR2 inhibitors in breast cancer. 
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1  Introduction 
1.1  Cancer 
Cancer is a disease defined by cells that are able to proliferate indefinitely, resist 
cell death, secrete self-sustaining growth signals, withstand anti-growth signals, as 
well as enhance angiogenesis and invade and metastasize (Hanahan & Weinberg, 
2011). As healthy tissue successfully manages to control all these aspects, cancer 
is considered a disease that is caused by genome instability (Hanahan & 
Weinberg, 2000). These neoplastic cells can arise from different tissues and 
organs. However, since mortality rates vary among different types of cancer, it 
becomes apparent that tumors are not merely clones of malignant cells, but rather 
complex organs (Egeblad, Nakasone, & Werb, 2010).  
 
1.1.1 Breast cancer 
Breast cancer develops from any cell of the mammary gland. However, most 
breast tumors (95 %) belong to the group of adenocarcinomas which means they 
developed from epithelial cells of the gland (Makki, 2015). Breast cancer accounts 
for about 25.1 % of all cancers and is the most common malignancy in women 
worldwide (Ghoncheh, Pournamdar, & Salehiniya, 2016). According to the World 
Health Organization (WHO), this disease is impacting 2.1 million women per year 
(WHO, 2018a).  
Apart from the female sex, the major risk factor for this disease is age. About 80 % 
of the cases are diagnosed in women above the age of 50 (Benson et al., 2009). 
With up to 10 % of breast cancer cases in western countries being linked to 
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mutations in certain genes, genetic predisposition also plays its part in developing 
this disease (McPherson, Steel, & Dixon, 2000). For instance, with breast cancer 
gene-1 (BRCA1) and -2 (BRCA2), two genes have been identified in which 
inherited mutations cause a higher risk of developing breast cancer (Ford et al., 
1998; King, Marks, & Mandell, 2003). Moreover, studies revealed that increased 
concentrations of endogenous estrogens in the serum are strongly associated with 
a higher risk for breast cancer in postmenopausal women (Key, Verkasalo, & 
Banks). Hence, as prevention it has already been suggested to influence the 
hormonal milieu of women at risk (McPherson et al., 2000). As several studies 
revealed that incidence rates are higher in more developed countries, 
corresponding rates in less developed countries are still lower. However, even in 
these countries rates are rising, suggesting external factors such as diet and 
alcohol consumption may also contribute to the pathogenesis of this oncological 
disorder (Key et al., 2001). 
 
1.1.2 Head and neck cancer 
More than 90 % of all head and neck cancers are squamous cell carcinomas. 
These can arise from squamous cells in mucous membranes in various subsites of 
the head and neck region: the hypopharynx, oropharynx, lip, oral cavity, 
nasopharynx, or larynx (Marur & Forastiere, 2008; Vigneswaran & Williams, 2014). 
Contrary to breast cancer, the squamous cell carcinoma of the head and neck only 
accounts for about 5-10 % of all cancers (Vigneswaran & Williams, 2014).  
Continuous exposure to tobacco and alcohol has been linked to the development 
of these malignancies (Marur & Forastiere, 2008). However, recently the infection 
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with high-risk human papillomaviruses (HPV), especially type 16, has also been 
shown to be implicated in the pathology of malignancies in the upper airway, such 
as respiratory papillomatosis and oropharyngeal cancer (Gillison et al., 2012; 
Sturgis & Cinciripini, 2007). Previously, these specific types of HPV were only 
linked to malignancies of the anogenital area (McKaig, Baric, & Olshan, 1998), as 
for instance, 80 % of cervical tumors are caused by these viruses (Bosch et al., 
1995). 
 
1.2 Therapeutic approaches of cancer 
In localized stage I tumors, surgery is still the most effective way of treatment, as it 
removes 100 % of all tumor cells. However, in many cases, with stage II or stage 
III malignancies, surgical approaches are combined with radiotherapy. Clinical 
radiotherapy had its debut in 1896 when Emil Grubbé treated advanced ulcerated 
breast cancer with X-rays (Bernier, Hall, & Giaccia, 2004). The aim of this form of 
therapy is to use high doses of radiation in order to eliminate cancer cells and 
shrink tumors. This method can either be employed pre-surgery (‘neo-adjuvant’), 
post-surgery (‘adjuvant’), or intraoperative. Radiotherapy alone is used in early 
stage or non-metastasized advanced head and neck cancers (Urruticoechea et al., 
2010). In case of more advanced tumors or stage IV malignancies, where the 
tumor has spread from its place of origin to another organ, systemic treatment is 
necessary. 
One example of a systemic treatment approach is the use of chemotherapeutics. 
The first cancer chemotherapeutics were developed in 1940. Whereas the early 
agents, the alkylating agents, were based on highly electrophilic reagents that 
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have the ability to react with cellular nucleophiles, the second group of cancer 
chemotherapeutics were antimetabolites (A. Baudino, 2015). Both reagents 
interfere with deoxyribonucleic acid (DNA) synthesis, thus, lead to cancer cell 
death. Nowadays, chemotherapy usually comprises a cocktail of many different 
reagents (Shewach & Kuchta, 2009) and can be used in several different ways: as 
neoadjuvant therapy (pre-surgery) in order to reduce the size of the tumor that has 
to be removed, adjuvant therapy (post-surgery) to ensure any tumor cells that 
might be left in patient are removed as well or concomitant without any surgery (A. 
Baudino, 2015). 
However, since chemotherapeutic reagents are used to treat the entire body, they 
also target and damage healthy tissue. Hence, side effects are usually quite 
severe (A. Baudino, 2015). It has become apparent that each tumor needs to be 
targeted directly and in unique ways in order to further reduce mortality, salvage 
healthy tissue and reduce side effects. Thus, the concept of targeted therapy 
evolved. These new targets include growth factors, signaling molecules, cell-cycle 
proteins, modulators of apoptosis, as well as molecules enhancing angiogenesis 
(Urruticoechea et al., 2010). In breast cancer, blocking the human epidermal 
growth factor receptor-2 (HER-2) has been shown to potently inhibit proliferation of 
breast cancer cells and is already used to treat HER-2 positive breast cancer 
patients (Plosker & Keam, 2006). Another example is the approach of targeting the 
epidermal growth factor receptor (Jablonska, Leschner, Westphal, Lienenklaus, & 
Weiss) with Cetuximab, a monoclonal antibody (mAb). It binds to the epidermal 
growth factor receptor with high affinity which has been shown to inhibit cell 
proliferation, enhance apoptosis, reduce angiogenesis, as well as invasiveness 
and metastasis (Harding, 2005). Another systemic treatment approach aiming to 
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target the tumor without causing severe side effects, is hormonal therapy. This 
treatment modality is often used in breast cancer, as certain subtypes were shown 
to be affected by hormone levels. The most common types of hormone therapy 
either aim to lower estrogen level within the entire system or to block estrogen 
from binding to its receptor on breast cancer cells (Burstein et al., 2018; Fabian, 
2007). 
 
1.3 Immunotherapy 
The most recent advances in treating cancer were made in the field of cancer 
immunotherapy. In order to develop solid tumors, cancer cells have to find 
mechanisms to avoid immune recognition and their subsequent elimination. The 
aim of immunotherapy is to use these mechanisms, interfere with them, and 
thereby inhibit tumor growth (Farkona, Diamandis, & Blasutig, 2016). For instance, 
blocking immune checkpoints which cancer cells employ to activate immune-
inhibitory pathways (Pardoll & Topalian, 1998). One of these is the cytotoxic T 
lymphocyte-associated protein-4 (CTLA-4), a receptor that down-regulates T cell 
activation upon binding one of its ligands, CD80 or CD86. By administering mAbs 
against CTLA-4, cancer cells can no longer attach to the immune checkpoint and 
anti-cancer T cell responses are fostered (Leach, Krummel, & Allison, 1996; Ribas 
et al., 2016). Indeed, clinical trials revealed promising results for melanoma 
patients with metastatic disease (Hodi et al., 2010) and led to the approval by the 
Food and Drug Administration (FDA) in 2011 (Farkona et al., 2016). Another 
checkpoint molecule is the programmed cell death protein-1 (PD-1) receptor, 
which is also expressed on T cells and inhibits proliferation, cytokine release, as 
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well as reduces their cytotoxic properties upon binding (Ishida, Agata, Shibahara, 
& Honjo, 1992; Keir, Butte, Freeman, & Sharpe, 2008). The most prominent ligand 
for PD-1 is PD-L1 which can be found on healthy, but also on cancer cells. 
Inhibiting the interaction of PD-1 and PD-L1 was shown to enhance T cell function 
and, thereby, increase antitumor activity of these immune cells (Topalian et al., 
2012). Several mAbs targeting PD-1 and PD-L1 have already been approved by 
the FDA after successful clinical trials. Recent studies also revealed other potential 
pathways such as lymphocyte activation gene 3 (Triebel et al., 1990) or the T cell 
immunoglobulin and mucin domain-containing 3 protein (Sakuishi et al., 2010), 
that could evolve as future therapeutic targets. Apart from the immune checkpoint 
inhibitors, another promising approach aiming to train the immune system to attack 
cancer, is the chimeric antigen receptor (CAR) T cell therapy. It involves isolating 
T cells from the patient, equipping these isolated immune cells with man-made 
antigen receptors that target the tumor, and transferring the improved T cells back 
into the patient (Almåsbak, Aarvak, & Vemuri, 2016; Farkona et al., 2016). 
Especially when it comes to hematologic cancers, this approach has shown very 
encouraging results (Chavez, Bachmeier, & Kharfan-Dabaja, 2019). Cancer 
immunotherapy also involves the use of monoclonal antibodies in order to target 
cancer-specific antigens, or of non-specific adjuvants in order to boost the immune 
system in general (Circelli, Tornesello, Buonaguro, & Buonaguro, 2017; Weiner, 
Surana, & Wang, 2010). Moreover, the development of cancer vaccines has been 
another immunotherapeutic strategy. This approach aims to initiate the process of 
activating the immune system through administering tumor antigens 
(Yaddanapudi, Mitchell, & Eaton, 2013). Despite all these advances, further 
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progress still needs to be made in this area. In order to continue this progress, it is 
of utter importance to understand how the immune system works. 
 
1.4 The immune system 
In a world full of pathogenic as well as non-pathogenic threats to the homeostasis 
of our bodies, the immune system is essential to ensure our wellbeing. Being a 
highly conserved system among many species, highlights once more its 
importance for our survival. Consequently, dysfunctions of the immune system can 
oppose a severe threat to our health: whereas overactivity can lead to allergies or 
autoimmune diseases, underactivity causes the body to be susceptible to 
infections or even the development of tumors (Parkin & Cohen, 2001). Hence, 
understanding the underlying mechanisms of immune responses is of great 
importance to be able to combat its dysfunctions.  
Historically, the immune system is divided into two parts: the innate and the 
adaptive immune system (Medzhitov & Janeway, 2000). 
 
1.4.1 The adaptive immune system 
Comparing the two parts of the immune system, the adaptive immune system 
represents the more fine-tuned immune response, meaning it operates with a 
small number of cells that possess high specificity for an individual threat (Bonilla 
& Oettgen, 2010; Chaplin, 2010). These immune responses are performed by T 
and B lymphocytes that are equipped with antigen specific receptors. Antigen 
presenting cells, such as macrophages and dendritic cells, phagocytose 
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pathogens and present small pieces on major histocompatibility complex (MHC) 
molecules on their surface. Subsequently, T and B lymphocytes can bind these via 
their specific receptors and thus, become activated. These cells against a specific 
antigen are able to persist within the body for the entire life which creates an 
immune memory that can be reactivated after another encounter with the target 
antigen and consequently, provide a rapid response when necessary (Bonilla & 
Oettgen, 2010). After developing in the bone marrow from hematopoietic stem 
cells that give rise to their lymphoid progenitor, T cells mature in the thymus and 
can be differentiated into the two types: cytotoxic CD8-positive (CD8+) T cells, with 
the primary function to eliminate infected cells, and CD4-positive (CD4+) T cells 
which are mainly responsible for the regulation of cellular and humoral immune 
responses (Chaplin, 2010; Cooper & Alder, 2006). CD4+ T cells can further be 
divided into T-helper (TH) cells and regulatory (Treg) T cells (Bonilla & Oettgen, 
2010). B lymphocytes are also developed from the lymphoid progenitor in the bone 
marrow. After activation, naive B cells can either develop into effector cells or 
plasma cells (Pieper, Grimbacher, & Eibel, 2013). Through becoming plasma cells, 
they are responsible for the humoral part of the adaptive immunity by producing 
and secreting antibodies (LeBien & Tedder, 2008). Antibodies can bind to their 
respective antigen, neutralize it, activate the complement system, and thereby, 
recruit more phagocytosing cells (Forthal, 2014).  
As both cell types are depending on the exposure to antigen presenting cells from 
the innate immune system and can also influence the innate response by 
secreting cytokines, it becomes apparent that the separation between the two 
immune responses is rather historical than just functional. 
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1.4.2 The innate immune system 
The innate immune system represents the body`s first line of defense against 
potential threats and provides a rapid, yet more unspecific response (Medzhitov & 
Janeway, 2000). In addition to physical barriers or defense mechanisms such as 
saliva or gastric acid, the innate immune system has to determine what represents 
a threat to the homeostasis in order to protect the body. Therefore, three ways of 
immune recognition have been proposed (Medzhitov & Janeway, 2002). For 
example, the host is able to determine “microbial non-self” by binding conserved 
microbial products only produced by microorganisms which are not part of the 
body. They are referred to as pathogen-associated molecular patterns, called 
PAMPs (Mogensen, 2009). Moreover, “missing self” is identified by applying 
markers that are always part of the “normal self”, which are unique for the host and 
not part of microorganisms. Several studies revealed that the immune system 
eliminates cells that do not express higher levels of the MHC class I protein. 
Consequently, the concept of missing self was introduced. MHC class I is 
expressed on all nucleated cells and only downregulated by viral infection or 
cellular damage, hence, serving as an fundamental marker for self-recognition 
(Ljunggren & Kärre, 1990). In order to detect “induced and altered self” the host 
relies on certain markers that are released upon infection or cellular damage, so 
called damage-associated molecular patterns (DAMPs) (Bianchi, 2007; Matzinger, 
2002). These three mechanisms are the door opener to activating the innate 
immune response. 
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1.4.2.1 Pathogen-associated molecular patterns, Damage-associated 
molecular patterns and their pattern-recognition receptors  
In order to recognize these structures and distinguish PAMPs as well as DAMPs, 
the host immune system has a set of receptors, called the pattern-recognition 
receptors (PRR). These receptors can either be membrane-associated, inside the 
cell, or present in a secreted form. Consequently, several different types of PRR 
can be distinguished: transmembrane toll-like receptors (TLR), cytosolic receptors 
such as nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) or 
retinoic acid inducible gene-I like receptors (RLR), and the secreted PRR (A. 
Iwasaki & Medzhitov, 2010). 
In total, 11 human TLRs and 13 TLRs in mice have been identified so far (X. 
Zhang & Mosser, 2008). TLRs located on the cell surface such as TLR4, TLR1 
and 2, TLR6, and TLR5 largely recognize PAMPs on the surface of microbes, 
whereas endosomal TLRs such as TLR3, TLR7, TLR8, and TLR9 recognize 
microbial nucleic acids, double-stranded (ds) (Srikrishna & Freeze), ribonucleic 
acid (RNA), single-stranded (ss) RNA, and dsDNA (Takeda & Akira, 2005). 
Examples for PAMPs expressed on the surface of pathogens include 
lipopolysaccharides (LPS) of gram-negative bacteria or peptidoglycan of gram-
negative and gram-positive bacteria (Mogensen, 2009). These receptors are 
mainly found on macrophages and dendritic cells but also on neutrophils, 
eosinophils, and epithelial cells (Chaplin, 2010; Akiko Iwasaki & Medzhitov, 2004). 
Cytosolic TLRs have been shown to detect viral proteins (Pichlmair & Reis e 
Sousa, 2007). Since the NLRs are cytosolic as well, they also bind soluble 
intracellular ligands. There are over 20 NLR encoding genes, all containing the 
following three domains: the C-terminal leucine-rich repeat (LRR) domain which is 
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responsible for binding microbial patterns, the NOD domain that is used to form 
multimeric complexes, and the N-terminal effector domain (Kanneganti, Lamkanfi, 
& Núñez, 2007). The NLRs are all able to sense pathogens but also recognize 
DAMPs released from injured or stressed tissue (Gallucci & Matzinger, 2001; 
Martinon, Mayor, & Tschopp, 2009). These DAMPs are molecules that are 
chemically completely unrelated, however, are all potent triggers of sterile 
inflammation (Hernandez, Huebener, & Schwabe, 2016). The secreted PRR are 
pattern-recognition proteins that contribute to initiating an immune response by 
mediating opsonization and activating the complement system: For instance, 
Dectin-1 can be activated through components of yeast. Collectins have the ability 
to recognize microbial carbohydrates and consequently, opsonize the microbe for 
phagocytosis. Pentraxins and Ficolins also recognize PAMPs and activate 
complement system (Bottazzi, Doni, Garlanda, & Mantovani, 2010). 
 
1.4.2.2 The innate immune response 
Once the host system has sensed danger, either by the binding of PAMPs or 
DAMPs to PRR, an inflammatory response is triggered, resulting in the recruitment 
of immune cells. The innate immune system comprises dendritic cells, mast cells, 
natural killer cells, as well as phagocytes such as macrophages, monocytes, and 
neutrophils (Chaplin, 2010). Together with eosinophils and basophils, neutrophils 
also belong to the group of polymorphonuclear leukocytes or granulocytes. Hence, 
these cells do not only display a varying shape of their nucleus but also contain 
antimicrobial granules in their cytoplasm (Geering, Stoeckle, Conus, & Simon, 
2013). Regarding the timescale of the immune response, neutrophils are recruited 
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to the site of infection first. Next, monocytes reach the target destination. All of 
these cells are highly phagocytic and therefore play an important role in the 
clearance of pathogens (S. Nourshargh & Alon, 2014; Zuchtriegel et al., 2015). 
 
1.4.2.2.1 The leukocyte recruitment cascade 
In order to get to sites of inflammation, leukocytes follow a distinct cascade of 
events which is referred to as the leukocyte adhesion cascade (Ley, Laudanna, 
Cybulsky, & Nourshargh, 2007) (Fig. 1.1). First, these immune cells are captured 
and roll on the luminal surface of postcapillary venular vessel walls (S. Nourshargh 
& Alon, 2014; Sperandio et al., 2003). This weak adhesive interaction is mostly 
mediated through a family of transmembrane glycoproteins: the selectins. L-
selectin/CD62L is known to be expressed on leukocytes, whereas E-selectin is 
found on endothelial cells and P-selectin/CD62P is expressed on activated 
endothelial cells and platelets (Kansas, 1996). All these selectins interact with P-
selectin glycoprotein ligand 1 (PSGL-1) (McEver & Cummings, 1997; Sperandio, 
2006), a ligand expressed on leukocytes and other cells. Hence, endothelial cells 
capture circulating leukocytes via interaction of E- and P-selectin with PSGL-1, 
despite constant blood flow. Several studies revealed that the shear stress arising 
from blood flow is even required for successful capturing of leukocytes (Lawrence, 
Kansas, Kunkel, & Ley, 1997). Furthermore, E-selectin/CD62E was also shown to 
bind to glycosylated CD44 and E-selectin ligand-1 (ESL-1) (Hidalgo, Peired, Wild, 
Vestweber, & Frenette, 2007). The binding of L-selectin to PSGL-1 results in 
leukocyte-leukocyte interactions, leading to secondary leukocyte capturing by 
already adhesive immune cells. Apart from their role in capturing and rolling, 
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studies revealed selectins also activate immune cells (Zarbock & Ley, 2009). 
Subsequently, this first weak adhesion is further strengthened by inflammatory 
cytokines that activate endothelial cells and thereby, cause an upregulation in 
adhesion molecules as well as chemokines and lipid chemoattractants (Campbell, 
Qin, Bacon, Mackay, & Butcher, 1996). These chemokines and chemoattractants 
are very strong activators of integrins - the main molecules responsible for the firm 
intravascular adherence of leukocytes. Inside-out signaling pathways from 
chemokines binding to chemokine receptors, result in switching their confirmation 
from low-affinity to extended-intermediate and finally high-affinity conformation 
with its open ligand-binding pocket (Arnaout, Mahalingam, & Xiong, 2005). This, 
for instance, allows the β2 integrins LFA-1/CD11a and Mac-1/CD11b, expressed 
on leukocytes, to bind to ICAM-1/CD54 or ICAM-2/CD102 on endothelial cells. The 
β1 integrin VLA-4/CD49d can bind to VCAM-1/CD106 both facilitating firm 
adhesion of the leukocytes to the endothelium (Ley et al., 2007). Moreover, it has 
been shown that further downstream this interaction activates the non-receptor 
tyrosine kinase Syk which has been shown to play an important role for neutrophil 
activation (Mócsai, Ruland, & Tybulewicz, 2010; Schymeinsky, Then, & Walzog, 
2005). Subsequently, leukocytes are crawling along the endothelial surface to find 
appropriate sites of transmigration. Guided by adherent platelets (Zuchtriegel et al. 
PLOS Biol 2016), leukocytes then transmigrate either via the transcellular route 
(roughly 10%), directly through the cell, or the paracellular pathway (roughly 90%) 
through endothelial-cell junctions. However, the route of transmigration seems to 
be dependent of the type of the underlying tissue, therefore, percentages vary 
(Maas, Soehnlein, & Viola, 2018; Phillipson et al., 2006; Woodfin et al., 2011). In 
order to arrive in the inflamed tissue, three different barriers have to be crossed: 
24 
 
Figure 1.1: A schematic overview of the leukocyte adhesion cascade. First, leukocytes roll on 
the endothelial surface mediated by members of the family of selectins, until they firmly adhere via 
interactions of members of the immunoglobulin superfamily with integrins. Next, leukocytes crawl 
along the endothelium in order to find appropriate sites for transmigration that allow them to enter 
the interstitium where they can finally resolve the inflammation. 
 
 
first the endothelial cells (passage time 2-5 min) guided by adhesion and signaling 
molecules such as JAM-A, PECAM-1, CD99, CD99L2, and ESAM (Bixel et al., 
2010; Muller, Weigl, Deng, & Phillips, 1993; Sussan Nourshargh, Krombach, & 
Dejana, 2006; Woodfin et al., 2007), second the endothelial-cell basement 
membrane, mainly consisting of collagen type IV and laminins (passage time 5-
15min), and finally the pericyte sheath. Once leukocytes have overcome that 
barrier, they move through the interstitium along a chemokine gradient to their 
target destination (S. Nourshargh, Hordijk, & Sixt, 2010). 
 
1.5 Neutrophil functions in acute inflammatory conditions 
The importance of neutrophils for resolving inflammation and maintaining 
homeostasis (Arandjelovic & Ravichandran, 2015) also becomes evident when 
looking at the number of these leukocytes in the body: in humans, 50-70 % of the 
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circulating leukocytes are neutrophils, and up to 2x1011 new neutrophils are 
produced daily under homeostatic conditions. Under inflammatory conditions these 
numbers can even raise higher (Mayadas, Cullere, & Lowell, 2014). Neutrophils 
develop from the myeloid precursor in the bone marrow (Borregaard, 2010) and 
their continuous production is ensured by the granulocyte-colony stimulating factor 
(G-CSF) (Lieschke et al., 1994). These immune cells play a critical role in the 
clearance of pathogens, with their phagocytic capabilities that allow them to 
internalize and destroy pathogens (Kennedy & DeLeo, 2009), and by releasing 
reactive oxygen species or antimicrobial proteins such as cathepsins or defensins 
(Häger, Cowland, & Borregaard, 2010). Another prominent mechanism how 
pathogens are eliminated by neutrophils is through the release of neutrophil 
extracellular traps (NETs). These traps mainly consist of histones as well as 
antimicrobial proteins and enzymes, such as neutrophil elastase (NE) (Brinkmann 
et al., 2004). Therefore, their main function is not only to capture pathogens and 
keep them from spreading, it is also to eliminate those germs (Kolaczkowska & 
Kubes, 2013). More recent findings revealed neutrophils can also take part in 
immunoregulatory functions: Activated neutrophils are capable of expressing and 
releasing cytokines, thereby influencing the recruitment of other immune cells 
(Cassatella, 1999). 
 
1.6 Neutrophil functions in tumors 
As described earlier, neutrophils are important for the clearance of pathogens and 
for the re-establishment of the body’s homeostasis under acute inflammatory 
conditions. However, under chronic inflammatory conditions neutrophil functions 
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can differ a fair bit (Soehnlein, Steffens, Hidalgo, & Weber, 2017). As tumors are 
often described as “wounds that do not heal”, this is also the case when it comes 
to malignancies (Dvorak, 1986). Neutrophils have been shown to be present in 
various types of solid tumors and their microenvironment (Jensen et al., 2012; Rao 
et al., 2012; Sokratis Trellakis et al., 2011). Whereas early studies described 
tumor-associated neutrophils as bystanders (Uribe-Querol & Rosales, 2015), 
several studies linked increased neutrophil numbers in blood and tumors to a poor 
outcome for the patients (Gentles et al., 2015; Shen et al., 2014; S. Trellakis et al., 
2011). These findings suggested a prognostic function of the neutrophil-to-
lymphocyte ratio in tumors and blood (Templeton et al., 2014). Thus, it has 
become apparent that neutrophils must display various functions when present in 
tumors or their environment (Fig. 1.2). For instance, by releasing large amounts of 
reactive oxygen species (ROS) or enzymes, neutrophils can cause DNA damage 
within epithelial cells and thus, help initiate tumor development (Antonio et al., 
2015; Knaapen, Güngör, Schins, Borm, & Van Schooten, 2006). Moreover, 
neutrophils release NE. By entering tumor cells, this serine protease has the ability 
to downregulate the insulin receptor subrate-1 (IRS-1), a negative regulator of 
phosphoinositide 3-kinase (PI3K). Hence, this leads to the activation of PI3K, 
resulting in increased tumor cell proliferation (Houghton et al., 2010). Furthermore 
tumor-associated neutrophils are large sources of matrix metalloproteinase 9 
(MMP9) (Coussens, Tinkle, Hanahan, & Werb, 2000), a factor well known for its 
role in tissue repair and regeneration (LeBert et al., 2015). A study by Bekes et al. 
revealed, neutrophils present within the tumor microenvironment produce MMP9, 
which contributes not only to angiogenesis but also tumor progression and 
metastasis (Bekes et al., 2011). In addition, by remodeling the extracellular matrix 
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(ECM), MMP9 can cause the release of vascular endothelial growth factor 
(VEGF).Hence, this further supports tumor angiogenesis as this factor was shown 
to induce endothelial cell proliferation and tubule formation in vitro (Bergers et al., 
2000; Nozawa, Chiu, & Hanahan, 2006). As it has also been revealed that VEGF 
has the ability to recruit more MMP9 rich neutrophils (Christoffersson et al., 2012), 
this can become a vicious cycle. In addition, tumor-associated neutrophils are able 
to directly release their intracellularly stored VEGF upon tumor necrosis factor 
(TNF) stimulation (Gaudry et al., 1997).  
Neutrophils can also contribute to tumor immunity by orchestrating the activity of 
other immune cells. For example by releasing Arginase-1 (Arg-1), neutrophils are 
capable of inhibiting T cell function (Dumitru, Moses, Trellakis, Lang, & Brandau, 
2012). Hence, depleting neutrophils in tumor-bearing mice lead to increased CD8+ 
T cell numbers in malignant tumors and, consequently, reduced tumor growth 
(Fridlender et al., 2009).  
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Figure 1.2: Neutrophil function within tumor development and progression. By releasing ROS 
or proteases neutrophils can cause damage to endothelial cells and thus, support carcinogenesis. 
The release of NE has been shown to enhance tumor cell proliferation. Moreover, neutrophils 
contain large amounts of MMP9, which can not only increase tumor progression and metastasis, 
but also lead to remodeling the ECM thereby causing the release of VEGF. This factor has the 
ability to support tumor angiogenesis. By releasing Arg-1, neutrophils can inhibit CD8+ T cell 
responses. (adapted by (Coffelt, Wellenstein, & de Visser, 2016)). 
 
 
 
In contrast to these findings, other studies suggested neutrophils can also engage 
in an anti-tumor role by promoting tumor cell clearance and by activating the 
immune system to combat the tumor (Eruslanov et al., 2014; Mantovani, 2018). 
Based on these contrasting findings, a separation of tumor-associated neutrophils 
into two groups has been proposed: the “N1” phenotype describes anti-
tumorigenic neutrophils and the “N2” phenotype refers to pro-tumorigenic 
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Table 1.1: Molecules associated with the N1 and N2 phenotype of neutrophils. The 
expression of several molecules differs between the N1 (anti-tumorigenic) and N2 (pro-
tumorigenic) phenotype of neutrophils. The N2 neutrophils show high expression levels of Arg-1, 
MMP9, or VEGF. In contrast, N1 neutrophils exhibit low expression levels of these molecules. 
neutrophils (Fridlender et al., 2009). These phenotypes can be distinguished by 
their expression levels of several molecules:  
N1 (anti-tumorigenic) N2 (pro-tumorigenic) 
Arg-1 low Arg-1 high 
MMP9 low MMP9 high 
VEGF low VEGF high 
C-C motif chemokines low C-C motif chemokines high 
 
The phenomenon of cells changing phenotypes under different circumstances 
such as chronic inflammation or tumors is still raising a lot of questions. It has 
been proposed that tumor-derived factors can play a role in the phenotypic switch 
from protecting neutrophils under acute inflammatory conditions to tumor-
supporting neutrophils (Powell & Huttenlocher, 2016). Furthermore, a recent study 
revealed blocking transforming growth factor-beta (TGF-β) in the tumor 
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microenvironment changes the pro-tumor “N2” neutrophils to the anti-tumor “N1” 
phenotype (Fridlender et al., 2009).  
 
1.6.1 Recruitment of neutrophils to tumors 
How neutrophils are recruited to tumors is still under debate. It is likely that the 
tumor and its microenvironment release cues that actively contribute to the 
recruitment of neutrophils (Powell & Huttenlocher, 2016). For instance, these 
signals can be chemokines and cytokines, such as interleukin (IL) CXCL8/IL-8 
(Xie, 2001). By expressing the receptors CXCR1/IL-8RA and CXCR2/IL-8RB, 
neutrophils can bind these cytokines and become activated (Luan et al., 1997; 
McDonald et al., 2010). Recent studies also revealed that by blocking CXCR2, 
myeloid leukocyte recruitment into the tumor was impaired which increased the 
efficacy of chemotherapy in breast cancer models (Acharyya et al., 2012). This 
further hints that interfering with neutrophil recruitment might be a potent 
therapeutic approach. Moreover, targeting cytokines instead of their receptors has 
already been suggested as a potential treatment option (Bekes et al., 2011) as IL-
8 was shown to be overexpressed in several carcinomas (Xie, 2001). However, 
this cytokine-receptor axis is most likely not the only pathway of neutrophil 
recruitment. Moreover, cytokines such as IL-1 or IL-6 are secreted and have 
already been implicated in supporting carcinogenesis (Ben-Neriah & Karin, 2011; 
Grivennikov, Greten, & Karin, 2010). It has also been proposed that tumors 
release DAMPs, as their high metabolism causes a lot of necrotic tissue and 
debris (Kreuzaler & Watson, 2012). For instance, these can be heat shock 
proteins, adenosine triphosphate (ATP), s100 proteins, uric acid, or mediators 
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such as high-mobility group box 1 (HMGB1). As mentioned earlier, these DAMPs 
can represent a potent trigger for sterile inflammation. Being constantly released 
by the tumor and its environment, this can cause a chronic state of inflammation, 
which has the ability to support tumor progression (Hernandez et al., 2016). By the 
binding of DAMPs to PRR, activation of inflammatory pathways will take place, 
resulting in the recruitment of inflammatory cells. It should also be mentioned that 
several studies revealed DAMPs are released during anti-tumor therapy 
(Srikrishna & Freeze, 2009), however, not leading to tumor progression, but 
causing a reinforcing antitumor immune response (Hernandez et al., 2016). 
 
1.7 Aged neutrophils 
Until not too long ago, neutrophils were thought to be relatively short lived cells 
that only remain in the circulation for a couple of hours. However, a more recent 
study revealed that human neutrophils can stay in the circulation for up to 5.4 days 
(Pillay et al., 2010). Furthermore, their expected shorter life span also led to the 
conclusion that neutrophils represent a homogenous cell population, once 
released from the bone marrow (Nicolas-Avila, Adrover, & Hidalgo, 2017). 
However, this view is rapidly changing over the past years as different subsets of 
neutrophils have now been described (Silvestre-Roig, Hidalgo, & Soehnlein, 
2016). For instance, several studies revealed that neutrophils undergo phenotypic 
changes during their time in the circulation, a process that is referred to as the 
“biological ageing” of neutrophils (J. M. Adrover, Nicolas-Avila, & Hidalgo, 2016). 
Once neutrophils are released from the bone marrow they are known to express 
high levels of CXCR2, L-selectin, and Ly6G. Several ex vivo as well as in vivo 
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Figure 1.3: Schematic overview of the neutrophil life cycle and their fate in inflammation. 
When non-aged neutrophils leave the bone marrow, they express high levels of CXCR2 and low 
levels of CXCR4 on their surface. However, during their time in the circulation neutrophils undergo 
phenotypic changes associated with an upregulation of the surface molecules CD11b, ICAM-
1/CD54, TLR4, and CXCR4 while downregulating surface expression of CXCR2. This process is 
referred to as biological ageing. Under steady state conditions, these aged neutrophils are 
recruited back in the bone marrow (BM) and eliminated via BM macrophages. In contrast, under 
inflammatory conditions these immune cells are the first immune cells recruited to the site of injury 
or infection. 
studies revealed that over time the expression levels of several molecules such as 
CXCR4/CD184 (Martin et al., 2003), CD11b, CD49d (J. M. Adrover et al., 
2016),TLR4, ICAM-1/CD54, and CD45 (D. Zhang et al., 2015) increases, whereas 
expression levels of CXCR2 (Eash, Means, White, & Link, 2009), L-selectin 
(Casanova-Acebes et al., 2013), and Ly6G (D. Zhang et al., 2015) were shown to 
decrease (Fig. 1.3).  
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Figure 1.4: Schematic overview of factors driving the biological ageing process in 
neutrophils. Binding of CXCL2 to CXCR2 induces the biological ageing process; binding of 
CXCL12 to CXCR4 antagonizes this process (adapted from (J. M. Adrover et al., 2019)).  
Regarding the factors that drive this biological ageing process in neutrophils, 
several different theories have been proposed: as this process begins once the 
cells are released into the circulation, it is likely to assume that a factor within the 
blood plasma is able to induce it. However, no specific factor could be determined 
just yet (J. M. Adrover et al., 2016). Moreover, a publication by Frenette’s group 
discussed the influences of the gut microbiota on the ageing of neutrophils. Germ-
free mice showed significantly reduced numbers of aged neutrophils, a phenotype 
that could be partly restored by administering bacteria-derived PRR agonists (D. 
Zhang et al., 2015). A very recent publication revealed that binding of neutrophil-
released CXCL2 to CXCR2 actually facilitates the ageing process in an autocrine 
manner, whereas binding of the ligand CXCL12 to its receptor CXCR4 
antagonizes it (J. M. Adrover et al., 2019). 
 
Studies regarding the function of aged neutrophils revealed that aged neutrophils, 
characterized through lower L-selectin expression, show more active β2 integrins, 
release more ROS and are more likely to form NETs (Brinkmann et al., 2004). 
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Furthermore, another study suggested that aged neutrophils serve as first 
responders during acute inflammation, further hinting towards aged neutrophils 
being highly reactive immune cells (Uhl et al., 2016). The fact that these cells 
seem to be aggressive immune cells also highlights the importance of a clearing 
mechanism in order to protect the circulation: by upregulating CXCR4 neutrophils 
can home back into the bone marrow, where they are cleared by bone marrow 
macrophages (Martin et al., 2003). Neutrophils that already migrated into tissues 
usually undergo apoptosis and are phagocytosed by resident tissue macrophages. 
This process is known to influence neutrophil granulopoesis via a negative 
feedback loop through IL-23 and IL-17, in order to ensure constant levels of 
neutrophils within the circulation (Stark et al., 2005). The role of aged neutrophils 
in chronic inflammatory conditions such as cancer, however, still raises a lot of 
questions. A very recent publication already pointed to the fact that neutrophil 
maturity may correlate with the complexity of neutrophil functions in cancer, and 
suggests targeting different stages of maturation may be a potential therapeutic 
approach (Mackey, Coffelt, & Carlin, 2019). 
 
1.8 The inflammasomes 
Inflammasomes represent a group of multimeric intracellular protein complexes, 
acting as signaling platforms upon detection of pathogenic or sterile stressors. The 
term “inflammasome” was first used by Tschopp and his group in 2002, describing 
a complex that regulated the activity of inflammatory caspases (Martinon et al., 
2009). Their main components are a sensor molecule, an adaptor protein called 
ASC (apoptosis-associated speck-like protein containing a CARD) and the 
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caspase-1. Several different types of inflammasomes can be distinguished, based 
on their sensor molecule, e.g. absent in melanoma 2 (AIM2), NLR family pyrin 
domain-containing 1 (NLRP1), NLR family pyrin domain-containing 3 (NLRP3) and 
NLR family CARD domain-containing protein 4 (NLRC4). Whereas NLRP1, 
NLRP3, and NLRC4 have a NLR sensor molecule, AIM2 has a DNA binding HIN 
domain (Latz, Xiao, & Stutz, 2013; Ozaki, Campbell, & Doyle, 2015).  
 
1.8.1 The NLRP3 inflammasome 
The NLRP3 inflammasome is one of the best characterized types of 
inflammasomes. As mentioned above, it consists of a sensor molecule that 
belongs to the NLR family, which can be further divided into an N-terminal effector 
domain, a central NACHT domain and a carboxy terminal, containing LRR (Ting et 
al., 2008). Once a threat is present within the cell, the usually auto-repressed 
NACHT domain is exposed. This causes the oligomerization of NLRP3 and ASC, 
which contains the caspase activation and recruitment (CARD) domain. 
Subsequently, the pro-caspase-1 is recruited. Next, CARD brings the monomers 
of pro-caspase-1 into close proximity which elicits the self-cleavage of caspase-1 
and creates its active form, resulting in proteolytically activating IL-1ß and IL-18 
(Latz et al., 2013; Tschopp & Schroder, 2010). The release of IL-1ß leads to the 
recruitment of innate immune cells, whereas IL-18 is important for the release of 
interferon-gamma and supports the activity of natural killer cells and T cells 
(Dinarello, 2006; He, Hara, & Núñez, 2016). 
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Figure 1.5: NLRP3 inflammasome complex formation. Once the cell is presented with a 
pathogen- or damage-associated threat, the auto-repression protecting the NLRP3 domains is 
removed. This leads to the oligomerization of NLRP3 and induces the recruitment of ASC, resulting 
in the activation of the caspse-1 and the secretion of the inflammatory cytokines IL-18 and IL-1β 
(adapted from (Tschopp & Schroder, 2010)). 
 
So far, several different types of immune cells are known to express the NLRP3 
inflammasome: macrophages, dendritic cells, neutrophils in the spleen and 
monocytes (Jo, Kim, Shin, & Sasakawa, 2016). In order to activate the NLRP3 
inflammasome, a two-step process has been proposed. The first step is a priming 
process, where components such as LPS bind to TLRs. This upregulates the 
nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) pathway 
and subsequently stimulates the transcription of NLRP3 inflammasome 
components (Bauernfeind et al., 2009; Franchi, Eigenbrod, & Núñez, 2009). For 
the second step of activation, three different possible ways have been described: 
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1) K+ efflux through a pore that is formed upon ATP binding to the P2X7 
receptor (Ketelut-Carneiro et al., 2015; Schmid-Burgk et al., 2015)  
2) Mitochondrial dysfunction that results in the production of ROS and the 
release of mitochondrial DNA into the cytosol (Lamkanfi & Dixit, 2014) 
3) Lysosomal rupture through the phagocytosis of particles, such as silica or 
Alum crystals, that results in the release of lysosomal proteases and 
cathepsin-B (Halle et al., 2008; Hornung et al., 2008) 
Activation of the NLRP3 inflammasome has been shown to be involved in many 
different pathologies. Therefore, deeper understanding of its mechanisms is 
crucial and could allow the development of novel therapeutics (Tschopp & 
Schroder, 2010). 
 
1.8.2 The NLRP3 inflammasome in tumors 
Persistent inflammation has been described to support carcinogenesis and tumor 
progression. Hence, it is not surprising that inflammasomes have been revealed to 
be abnormally expressed and activated in various types of tumors (H. Wang et al., 
2018). Especially, activation of the NLRP3 inflammasome has been subject to 
many studies. Some studies point to a protective function of inflammasome 
activation when it comes to an immune response against the tumor (Gasparoto et 
al., 2014). However, most studies revealed that the NLRP3 inflammasome 
contributes to tumor initiation, growth, as well as metastasis (Bruchard et al., 2012; 
Huang et al., 2017; H. Wang et al., 2018). Moreover, is was shown that all 
inflammasome components, such as NLRP3, caspase-1, as well as IL-1ß and IL-
18 are highly expressed in head and neck squamous cell carcinoma (HNSCC) cell 
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lines as well as a mouse HNSCC model (Huang et al., 2017). In breast cancer, 
elevated expression levels of IL-1ß have been shown to be associated with 
carcinogenesis (Jin et al., 1997). Overall, these findings point to the NLRP3 
inflammasome being an emerging target in tumor development and progression. 
However, with contrasting results its role seems to be complex. 
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2 Objective 
According to the World Health Organization, cancer is the second leading cause of 
death worldwide accounting for the passing of 9.6 million people in 2018 (WHO, 
2018b). Until today, treatment options are still limited. Thus, it is of great 
importance to further uncover mechanisms tumors employ to progress, allowing 
the identification of future therapeutic targets. As neutrophils have been shown to 
play a critical role in tumor initiation and progression (see 1.2.1), and their 
presence has even been suggested as a prognostic value, targeting these immune 
cells might represent a promising strategy. 
Therefore, the aim of the present studies was to unravel i) what causes the 
recruitment of neutrophils to the tumor, ii) what are the underlying mechanisms, 
and iii) what exactly is their phenotype and function, once present in the tumor and 
its microenvironment.   
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3 Material and Methods 
3.1 Ethics 
All following animal experiments were conducted from 2016 to 2019 at the Walter-
Brendel Centre of Experimental Medicine of the LMU München (Munich, 
Germany), after approval by the local governmental authorities (“Regierung von 
Oberbayern”, 02-16-17, 02-17-68 and Reichel 14) along their guidelines to ensure 
animal welfare. 
 
3.2 Animals 
For the experiments different mouse strains, purchased by Charles River 
(Sulzfeld, Germany) at the age of 6 to 8 weeks and weighing between 15-18 g, 
were used. Experiments with a mouse squamous cell carcinoma cell line (SCC 
VII) were conducted with male C3H/HeNCrl mice. For analyses with a mouse 
mammary carcinoma cell line (4T1), female BALB/cJ mice were used. All 
remaining experiments were performed with male C57BL/6NCrl mice. Animals 
were housed in the Walter Brendel Centre of Experimental Medicine of LMU 
München under standard conditions (22 ± 2 °C, 30 – 60 % humidity, 12 h light/dark 
cycle, lights on at 7 am) in cages of 3, with access to food and water ad libitum. 
 
3.3 Anesthesia 
During all experiments and surgical procedures, mice were anesthetized using a 
mixture of ketamine (100 mg/kg, zoetis, Parsippany, New Jersey, USA) and 
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xylazine (10 mg/kg, Bayer, Leverkusen, Germany) diluted in saline (Fresenius 
Kabi, Bad Homburg vor der Höhe, Germany) at a ratio of 1.5:0.5:7. Anesthesia 
was administered via intraperitoneal (i.p.) injection. Constant body temperature of 
mice was ensured by using heating plates and heating lamps. 
 
3.4 Cell lines 
In order to investigate leukocyte trafficking to tumors, the mouse head and neck 
squamous cell carcinoma cell line SCC VII and the mouse mammary carcinoma 
cell line 4T1 were obtained from Kirsten Lauber (Department of Radiotherapy and 
Radiation Oncology, LMU München). Tumor cells were cultured in RPMI (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) media, supplemented with 10 % 
FBS (Biochrom, Berlin, Germany) and 1 % HEPES (PromoCell, Heidelberg, 
Germany) at 37 °C and 5 % CO2. Furthermore, mouse brain endothelial cells 
(bEnd.3) were purchased from ATCC (Manassas, Virginia, USA) and cultured in 
DMEM (ATCC) supplemented with 10 % FBS at 37 °C and 5 % CO2. 
 
3.4.1 Thawing of cells 
Cryovials (Thermo Fisher Scientific) containing the different cell lines were kept in 
liquid nitrogen for their long-term storage. In order to culture cells, vials were 
thawed and diluted in 10 ml of the appropriate medium. After transferring the 
suspension in cell culture flasks (Corning, Corning, New York, USA), cells were 
cultured at 37 °C and 5 % CO2. Medium was changed the following day. 
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3.4.2 Splitting of cells 
In order to split the cells, medium was removed and cells were washed with 10 ml 
phosphate buffered saline (PBS). Next, 2 ml of trypsin (PAN-Biotech, Aidenbach, 
Germany) were added to the flask and incubation at 37 °C for approximately 5 min 
followed, until complete detachment of all cells. After resuspending the cell 
suspension in 8 ml of medium, cells were collected in a Falcon tube and 
centrifuged. Subsequently, cells were either diluted 1:10 in a new flask or used for 
experiments. 
 
3.4.3 Determination of cell numbers 
In order to determine numbers of cultured cells, 50 µl of cell suspension were 
diluted with trypan blue solution (Sigma Aldrich, St. Louis, Missouri, USA) at a ratio 
of 1:1, which allows distinguishing live and dead cells. Next, the suspension was 
placed in a Neubauer cell counting chamber (0.1 mm depth, Laboroptik, Lancing, 
UK). The number of live cells was calculated by using the following equation: 
Number of cells/ml = mean x dilution factor (2) x area (104)  
 
3.5 Animal models 
3.5.1 Orthotopic tumor models 
In order to study leukocyte trafficking to solid tumors of SCC VII (floor of mouth) 
and 4T1 (breast) cancer cells, an orthotopic mouse model was established.  
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Figure 2.1: Experimental protocol to analyze leukocyte trafficking to solid tumors. First, 
tumor cells or saline were injected in an orthotopic manner. On day 14 (D14) tumor and blood 
samples were collected and analyzed by multi-channel flow cytometry. In selected experiments, the 
relative age of neutrophils was determined after application (i.v.) of BrdU on day 11 (D11), 72 h 
prior to multi-channel flow cytometry analysis. 
3.5.1.1 Experimental design and groups 
In a first set of experiments, the different subsets of leukocytes in the tumors were 
characterized. In addition, neutrophils in the blood of tumor-bearing mice with a 
special regard to the relative age of neutrophils, were analyzed according to the 
following protocol: 
 
Experiments were repeated in neutropenic mice. For this purpose, tumor-bearing 
mice were treated continuously for one week with a neutrophil-depleting anti-Ly6G 
mAb (100 µg, clone 1A8, BioXCell, Lebanon, New Hampshire, USA) via tail vein 
injections every 48 h, starting at the day of tumor cell injection:  
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Figure 2.2: Experimental protocol to analyze leukocyte subsets present in solid tumors after 
neutrophil depletion. Tumor cells or saline were injected in an orthotopic manner. On day 7 (D7) 
after tumor cell injection, tumor and blood samples were collected and analyzed by multi-channel 
flow cytometry. In order to deplete neutrophils in tumor-bearing mice, i.v. injections of anti-Ly6G 
mAb were performed every 48 h according to previously published protocols. 
Figure 2.3: Experimental protocol to analyze leukocyte subsets in solid tumors after 
treatment with inhibitors or antagonists. After injecting tumor cells or saline (orthotopically), 
samples were collected on day 14 (D14) and analyzed by multi-channel flow cytometry. I.p. 
injections of a NLRP3 inflammasome inhibitor were performed on day 0 (D0), day 1 (D1), day 3 
(D3), day 6 (D6), and day 8 (D8), a CXCR4 inhibitor every 48 h, and a CXCR2 inhibitor every day 
according to previously published protocols. 
 
In another set of experiments, the presence of aged neutrophils in tumors were 
analyzed after treatment with a NLRP3 inflammasome inhibitor (MCC950; 10 
mg/kg, InvivoGen, San Diego, California, USA), a CXCR4 inhibitor (AMD 3100, 5 
µg/kg, Tocris, Bristol, England), or a CXCR2 inhibitor (SB 225002, 5 mg/kg, 
Tocris) in the following manner: 
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3.5.1.2 Tumor cell injection 
Tumor cells (at a concentration of 2 x 105 cells/20 µl) were injected in an orthotopic 
manner: SCC VII tumor cells subcutaneously into the floor of the mouth of 
C3H/HeNCrl mice and 4T1 tumor cells subcutaneously into the left chest of 
BALB/cJ mice. Control mice received saline injections. 
 
3.5.1.3 Tissue sample preparation 
Two weeks after tumor cell injection, tumor tissue and blood were harvested. 
Anesthetized mice were sacrificed by dislocation of the neck. Next, whole blood 
was taken from the vena cava by opening the peritoneal cavity and exposing the 
vessel. Using a 20 G cannula (Becton Dickinson, Franklin Lakes, New Jersey, 
USA), the vein was punctured and blood was carefully taken with a syringe 
containing 10 µl heparin (25000 i.E, ratiopharm, Ulm, Germany). Tumors were 
excised and weighed, before homogenizing in 15 ml of saline. By pouring the 
homogenized tissue through a cell strainer (Corning, 70 µm), a single cell 
suspension was obtained and collected in a 50 ml Falcon tube (Corning). After 
centrifugation at 1500 rpm for 5 min (Rotina 35R, Hettich, Kirchlengern, Germany) 
at room temperature (RT), each cell pellet from the tumor was resuspended in 500 
µl of PBS. Using 50 µl of the samples, the overall leukocyte count was determined 
with the ProCyte Hematology analyzer (IDEXX, Westbrook, Maine, USA). 
Subsequently, 100 µl of each anticoagulated blood and tumor sample was placed 
in a FACS tube (Corning) and immunostained with antibodies directed against 
CD45 APC-Cy7 (BD Bioscience, San Jose, California, USA), CD11b FITC (BD 
Bioscience), or CD11b PerCp-Cy5 (eBioscience, SanDiego, California, USA), Gr-1 
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PE (eBioscience), F4/80 efluor450 (eBioscience), and CXCR4 APC (Biolegend, 
San Diego, California, USA) for 30 min on ice. In selected experiments, T 
lymphocytes were identified by anti-CD8a PE-Cy7 mAb (eBioscience) and anti-
CD4 AF700 mAb (eBioscience). Subsequently, erythrocytes were lysed with 1 ml 
of lysing solution (BD FACS Lysing solution, BD Bioscience) diluted in Aqua inj. 
(B.Braun, Melsungen, Germany) 1:10 for 10 min at RT. After washing with PBS 
twice, samples were resuspended in 200 µl PBS and analyzed via multi-channel 
flow cytometry. 
 
3.5.1.3.1 Differentiation between aged and non-aged neutrophils 
To determine the relative age of neutrophils, a pulse labelling technique with 5-
Bromdesoxyuridin (BrdU, FITC BrdU Flow kit, BD Bioscience) was used according 
to previously published protocols (Uhl et al., 2016). BrdU is a thymidine analogue 
incorporated into DNA during its replication. By denaturing DNA, incorporated 
BrdU is accessible for staining and hence, for its detection. Consequently, non-
aged neutrophils released from the bone marrow appear BrdUpositive, whereas 
(more) aged (circulating) neutrophils are BrdUnegative when analyzed by flow 
cytometry. Therefore, 72 h prior to the experiment mice received a single 
intravenous (i.v.) injection via the tail vein (2.5 mg/kg) in order to label neutrophil 
precursors in the bone marrow. Next, tissue and blood was prepared and 
immunostained as described previously in 3.5.1.3. Subsequently, the BrdU 
protocol followed according to the manufacturer description in the BrdU Flow kit. 
Briefly, samples were washed with 1 ml PBS (1500 rpm, 5 min, RT). 
Subsequently, a first fixation step followed with a 100 µl of Cytofix/Cytoperm buffer 
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for 15 min at RT. After washing the samples with 1 ml of the previously prepared 1 
x BD Perm and wash buffer, another permeabilization step with 100 µl of the 
Cytoperm buffer plus followed for 10 min on ice. Next, cells were washed in 1 x BD 
Perm and wash buffer again, before refixation in another 100 µl of BD 
Cytoperm/Cytofix buffer for 5 min on ice was performed. Another washing step in 1 
x BD Perm and wash buffer followed, before samples were treated with 100 µl of 
DNAse (300 µg/ml) for 1 h at 37 °C in order to make the incorporated BrdU 
accessible. Next, cells were washed in 1 x BD Perm and wash buffer again and 
finally incubation with the antibody directed against BrdU (50 µl of the 1:50 diluted 
antibody) for 20 min at RT followed. After another last washing step cells were 
resuspended in 200 µl and measured via multichannel flow cytometry. 
 
3.5.2 Heterotopic tumor models 
In order to analyze neutrophil responses in the tumor and its microenvironment, a 
heterotopic tumor model was established in the mouse ear, enabling in vivo 
microscopy (IVM) analyses.  
 
3.5.2.1 Experimental design and groups 
In a first set of experiments, neutrophil trafficking to the tumor and its 
microenvironment in tumor-bearing mice was assessed according to the following 
protocol: 
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Figure 2.4: Experimental protocol for intravital imaging of the tumor and its 
microenvironment. Tumor cells or saline were injected into the left mouse ear. In vivo microscopy 
(IVM) was performed on day 3 (D3) and day 7 (D7). 
Figure 2.5: Experimental protocol for in vivo imaging of the tumor and its 
microenvironment. Tumor cells or saline were injected into the left mouse ear. In vivo microscopy 
(IVM) was performed on day 3 (D3) and day 7 (D7) directly after treatment with the NLRP3 
inflammasome inhibitor via i.p. injections on day 0 (D0), day 1 (D1), D3 and day 6 (D6). 
 
 
Next, neutrophil responses in tumor-bearing mice treated with the NLRP3 
inflammasome inhibitor MCC950 (10 mg/kg) were investigated.  
 
To directly analyze intravascular interactions of aged and non-aged neutrophils in 
the tumor and its microenvironment, adoptive cell transfer experiments were 
conducted according to previously published protocols (see 3.5.2.4) (Uhl et al., 
2016). 
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Figure 2.6: Experimental protocol for adoptive cell transfers. Neutrophils were isolated from 
either anti-P- and anti-E-selectin treated, or isotype control antibody-treated WT donor mice. After 
immunostaining the cells with anti-Ly6G mAb, neutrophils were injected i.v. into tumor-bearing 
mice on D7, before IVM was performed. 
 
Moreover, the tumor imaging ear model was used to investigate angiogenesis in 
the tumor and its microenvironment in neutrophil-depleted tumor-bearing mice 
(see 3.5.1.1) and vehicle-treated tumor-bearing mice on day 7 after tumor 
cell/vehicle injection. 
 
3.5.2.2 Tumor cell injection 
Anesthetized mice were placed on a custom-made microscopy stage and their left 
outer ear was fixed onto a stack of glass slides with silicone (Kurt Obermeier 
GmbH & Co. KG, Bad Berleburg, Germany). In order to apply tumor cells, a 
polystyrene catheter (Smiths Medical, Ashford, UK) prepared with a 30 G cannula 
(B.Braun) was used. After disinfecting the ear (Bacilol, Hartmann, Heidenheim, 
Germany) the tumor cells were injected into the subcutaneous layer of the left 
outer ear, in a concentration of 2 x 105 cells/20 µl. Control mice received saline 
injections.  
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3.5.2.3 In vivo ear imaging 
Neutrophil responses in the tumor and peri-tumoral microvasculature were 
visualized using anti-Ly6G PE mAb (BD Bioscience). For injecting the antibody, a 
polystyrene catheter prepared with a 30 G cannula was used. Mice received 
anesthesia and were fixed onto a microscopy stage. Subsequently, the animal’s 
tail was disinfected and the antibody was injected into the tail vain in a total 
volume of 100 µl. For analyzing the vessel network in the tumor and its 
microenvironment, mice received an i.v. injection of FITC Dextran (150 kDa, 50 µl, 
Sigma Aldrich) in the same manner. 
Finally, the outer ear of mice was placed on a custom-made microscopy stage and 
lightly fixed with silicone gel. By adding ultrasound gel (SONOSID®, Asid Bonz, 
Herrenberg, Germany) on top of the ear, imaging of postcapillary venules or the 
architecture of the microvasculature followed.  
 
3.5.2.4 Adoptive cell transfer experiments 
To analyze intravascular interactions of aged and non-aged neutrophils in the 
tumor and its microenvironment, adoptive cell transfer experiments were 
performed. In order to obtain aged neutrophils, wildtype (WT) donor mice were 
treated with anti-E-selectin (50 µg, BD Bioscience) and anti-P-selectin (50 µg, 
Biolegend) mAbs i.v. 48 h and 24 h before the cell transfer experiments via tail 
vein injection. This inhibits the recruitment of aged neutrophils back to bone 
marrow, liver, and spleen, thus leading to the enrichment of aged neutrophils in 
the circulation. WT donor mice used for the transfer of non-aged neutrophils, 
received saline injections. Subsequently, blood was taken from the vena cava as 
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Figure 2.7: Experimental protocol for IVM of the M. cremaster. Alum crystals or saline were 
injected into the scrotum of WT mice. 3 h or 6 h later, the surgical preparation of the M. cremaster 
and in vivo microscopy (IVM) followed. 
 
described before (see 3.5.1.3) and incubated with HetaSep (STEMCELL 
Technologies, Vancouver, Canada) in a ratio of 1:5 for 5 min at 37 °C. By red 
blood cell aggregation and sedimentation, samples were cleared from red blood 
cells. Next, neutrophils were stained with anti-Ly6G PE (BD Bioscience) for 20 min 
at RT. After washing the cells with PBS, i.v. injection into the receiving tumor-
bearing mice followed, 30 min before in vivo ear imaging was performed. 
 
3.5.3 M. Cremaster assay 
The cremaster muscle represents a well-established model to investigate the 
different steps of leukocyte recruitment. 
 
3.5.3.1 Experimental design and groups 
This model was used to investigate the effects of NLRP3 inflammasome activation 
on leukocyte recruitment at different time points. 
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3.5.3.2 Intrascrotal stimulation 
In order to stimulate activation of the NLRP3 inflammasome, 10 µg of Alum 
crystals (InvivoGen) diluted in a total volume of 350 µl saline, were injected into 
the scrotum of C57BL/6NCrl mice using a 30 G cannula, followed by incubation for 
3 h or 6 h. Control mice received saline injections.  
 
3.5.3.3 Surgical preparation of the intra-arterial catheter and the cremaster 
muscle 
The preparation of the mouse cremaster muscle was performed under a surgical 
microscope (M651, Leica, Wetzlar, Germany) similar to the previous description by 
Baez (Baez, 1973), with minor adjustments. In order to allow administration of 
antibodies, a catheter was placed into the femoral artery in a retrograde manner. 
Through a ventral incision, the scrotum was opened and the right cremaster 
muscle was exteriorized. Connective tissue around the cremaster muscle was 
carefully removed. Next, the muscle was cut and opened ventrally to allow 
spreading over a pedestal in a plexiglas tray of a custom-made microscopy stage. 
To enhance visibility of the fluorescence-labeled antibodies, the pedestal 
contained a black coverslip. After detaching the epididymis and testicle, they were 
placed back into the abdominal cavity. Careful electrocautery was used to stop 
any bleeding along the edges of the cremaster muscle. Throughout surgical 
preparation and in vivo microscopy, the muscle was continuously superfused with 
warm buffered saline. In order to visualize the leukocytes of interest, cells were 
immunostained with anti-Gr-1 PE, anti-CD115 AF594 mAbs (Biolegend). 
Subsequently, IVM of postcapillary venules followed. After IVM, blood was taken 
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Figure 2.8: Experimental protocol for the peritonitis assay. The different stimuli or saline were 
injected i.p. into WT mice. 6 h later, a peritoneal lavage was performed and samples were analyzed 
by flow cytometry. 
 
from the vena cava as described in 3.5.1.3 and systemic leukocyte counts were 
determined using a ProCyte Hematology analyzer. 
 
3.5.4 Peritonitis assay 
The peritonitis assay represents a well-established model to assess leukocyte 
recruitment to the peritoneal cavity after i.p. injection of various stimuli. 
 
3.5.4.1 Experimental design and groups 
In a first set of experiments, the leukocyte-recruiting properties of DAMPs such as 
HMGB1 (Biolegend), s100A8/A9 (Biolegend), or monosodium urate (MSU) 
crystals (InvivoGen) were investigated. Furthermore, the effect of the different 
inflammasome-activating substances on leukocyte recruitment such as poly (da:dt) 
(InvivoGen), flagellin (FLA-ST, InvivoGen), muramyl dipeptide (MDP, InvivoGen), 
or Alum crystals was assessed with the peritonitis model in the following manner: 
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3.5.4.2 Induction through intraperitoneal injection 
Stimuli were injected into the peritoneal cavity of WT mice using a 30 G cannula, 
in a total volume of 400 µl, diluted with saline: HMGB1 in a concentration of 1 
µg/ml, s100A8/A9 in 1 µg/ml and MSU in a concentration of 10 µg/ml. The 
inflammasome-activating substances were injected in the following concentrations: 
poly da:dt 10 µg/ml, FLA-ST in 10 µg/ml, and MDP or Alum crystals in 10 µg/ml 
saline. Control mice received saline injections.  
 
3.5.4.2.1 Sample preparation 
Anesthetized mice were sacrificed 6 h after i.p. injection of the stimuli, by 
dislocation of the neck. Using a 30 G cannula, 10 ml of cold PBS were injected 
into the right side of the mouse’s peritoneum. Next, their peritoneal cavity was 
washed by inserting a butterfly cannula (14G OPTIVA®, Smiths Medical) into the 
left side of mouse peritoneum. In total, 10 ml of peritoneal fluid was collected in a 
15 ml Falcon tube. Next, samples were centrifuged for 5 min at 1500 rpm at RT, 
supernatants were discarded and the pellets were resuspended in 500 µl of PBS. 
Using 50 µl of the cell suspension, the overall leukocyte count of the peritoneal 
lavage fluid was analyzed with a ProCyte Hematology analyzer. Of each sample, 
100 µl were placed into FACS tubes and cells were immunostained with antibodies 
directed against CD45 (APC-Cy7), CD11b (FITC), Gr-1 (PE), F4/80 (eFluor450) 
and CXCR4 (APC) for 30 min on ice. After lysing erythrocytes with 1 ml of lysing 
solution, followed by two washing steps with PBS, samples were resuspended in 
200 µl PBS and analyzed using a multi-channel flow cytometer. 
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3.5.4.2.2 Differentiation between aged and non-aged neutrophils 
The relative chronological age of neutrophils recruited to the peritoneal cavity upon 
NLRP3 inflammasome activation was analyzed using a pulse labeling technique 
with 5-BrdU. First, samples were prepared as described previously (see 3.5.4.2.1), 
then cells were immunostained with the following antibodies: anti-CD45 APC-Cy7, 
anti-CD11b PerCp-Cy5, anti-Gr-1 PE, anti-F4/80 eFluor450, and anti-CXCR4 
APC. Afterwards, the BrdU Flow kit protocol followed, as described in 3.5.1.3.1. 
 
3.6 Flow cytometry 
Employing multi-channel flow cytometry (Gallios, Beckman Coulter Inc, Brea, 
California, USA), myeloid leukocytes were identified by their expression of CD45 
and CD11b. Using Gr-1 and F4/80, these cells were further distinguished into 
neutrophils (Gr-1high, F4/80low) classical monocytes (Gr-1high, F4/80high), and non-
classical monocytes (Gr-1low, F4/80high). Neutrophils were further differentiated into 
BrdUpositive CXCR4low (non-aged) and BrdUnegative CXCR4high cells (aged). 
Lymphoid leukocytes such as T cells were identified as CD11blow and CD4positive or 
CD8apositive. All results were quantified by using the FlowJo software (Treestar, 
Ashland, Oregon, USA). 
 
3.7 In vivo microscopy 
In vivo microscopy was performed using an AxioTech-Vario 100 Microscope 
(Zeiss MicroImaging GmbH, Goettingen, Germany), equipped with a Colibiri LED 
light source (Zeiss MicroImaging GmbH) for fluorescence epi-illumination 
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microscopy. All images were taken using a 40x water immersion lens (0.5 NA, 
Zeiss MicroImaging Gmbh). Images of the architecture of the analyzed 
microvasculature were obtained with a 10x water immersion lens. Microscopy 
videos were obtained by an AxioCam Hsm digital camera, and processed with the 
AxioVision 4.6 software (Zeiss MicroImaging GmbH). 
Analysis of the in vivo microscopy videos was performed by using the imaging 
software Fiji (Schindelin et al., 2012). In the heterotopic tumor model, neutrophils 
were identified as Ly6Gpositive cells. In the cremaster muscle assay, neutrophils 
were identified as Gr-1postive CD115negative cells, classical monocytes as Gr-1positive 
CD115positve cells, and non-classical monocytes as Gr-1negative CD115positve cells. 
Leukocytes moving slower than the associated blood flow were defined as rolling 
leukocytes and quantified for 60 s per venule. For firmly adherent leukocytes, a 
threshold for resting in the associated blood flow for >30 s, was determined and 
counted on the luminal surface per 100 μm vessel length. Microcirculatory 
parameters such as diameter and length of the vessel were determined in Fiji. 
The microvascular architecture in tumor and its environment was analyzed by 
using the Skeleton plugin of Fiji. Briefly, the plugin is able to create skeletonized 
maps of the vessel network which allows determination of the number of branches 
per high power field, the number of junctions per high power field as well as the 
average branch length. The vessel density was determined as the number of 
branches multiplied with the average branch length and divided by the area of the 
high power field.  
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3.8 Tumorigenicity of neutrophils 
To characterize the phenotype of neutrophils after NLRP3 inflammasome 
activation, a peritonitis assay was performed as described previously (see 3.5.4). 
Antibody staining, depending on the fluorescence label of each N1/N2 marker 
followed in the according manner:  
PE - labeled marker FITC - labeled marker Non - labeled marker 
anti-CD45 APC-Cy7 anti-CD45 APC-Cy7 anti-CD45 APC-Cy7 
anti-CD11b PerCp-Cy5 anti-CD11b PerCp-Cy5 anti-CD11b PerCp-Cy5 
anti-Gr-1 AF488 anti-Gr-1 PE anti-Gr-1 PE 
anti-F4/80 eFluor450 anti-F4/80 eFluor450 anti-F4/80 eFluor450 
anti-CXCR4 APC anti-CXCR4 APC anti-CXCR4 APC 
 
Subsequently, further immunostaining of each sample with an antibody either 
directed against NE (rat, R&D Systems, Minneapolis, Minnesota, USA), MMP9 
FITC (StressMarq Biosciences, Victoria, Canada), VEGF FITC (Novus Biologicals, 
Centennial, Colorado, USA), CCL5 PE (Biolegend), CCL3 PE (eBioscience), or 
Arg-1 PE (R&D Systems) was performed for 30 min on ice. For the unlabeled NE 
antibody, a secondary antibody (goat anti-rat AF488, Thermo Fisher Scientific) 
followed for 20 min at RT before continuing the regular protocol of lysing 
Table 2.1: Experimental protocol for immunostaining according the different surface 
markers.  
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erythrocytes and washing the samples. After resuspending the samples in 200 µl 
PBS, expression levels of the molecules were measured on neutrophils via flow 
cytometry. 
 
3.9 Activation of neutrophils 
3.9.1 Analysis of integrin expression on neutrophils in the blood 
As a parameter for neutrophil activation, surface expression of the integrins 
CD11a, CD11b, and CD49d was assessed in murine neutrophils after NLRP3 
inflammasome activation by flow cytometry. To this end, whole blood was 
harvested from WT C57BL/6NCrl mice as described above (see 3.5.1.3). In each 
FACS tube, 100 µl of anticoagulated blood sample were placed and incubated for 
30 min at 37 °C either with Alum crystals (10 µg), TNF (100 ng, R&D Systems), or 
PBS as negative control. After washing the samples twice with PBS, cells were 
labeled with antibodies directed against CD45 APC-Cy7, CD11b PerCp-Cy5, Gr-1 
PE, F4/80 eFluor 450, CXCR4 APC, and CD11a (FITC, eBioscience) or CD49d 
(FITC, eBioscience). Erythrocytes were lysed using lysing solution as described 
before. Finally, after another washing step with PBS, samples were resuspended 
in 200 µl PBS and integrin expression was measured by flow cytometry. 
 
3.9.2 Analysis of ICAM-1/CD54-Fc binding properties of neutrophils 
As a measure of conformational changes of β2 integrins, binding of ICAM-1/CD54-
Fc to neutrophils was assessed. For this purpose, blood was carefully taken from 
the vena cava as described previously (see 3.5.1.3). Subsequently, 50 µl of each 
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anticoagulated blood sample were placed into FACS tubes and suspended in 50 µl 
of Hanks balanced salt solution containing 1 mM CaCl2 and MgCl2 (Life 
Technologies, Carlsbad, California, USA). Next, incubation with the according 
stimuli, either phorbol-12-myristat-13-acetat (PMA, 50 ng/ml, Sigma Aldrich) as a 
positive control, Alum crystals (10 µg), or PBS as a negative control followed for 
30 min at 37 °C, before adding ICAM-1/CD54-Fc (10 μg/ml, R&D Systems) and 
PE-conjugated anti-human IgG1 (Fc-specific, Southern Biotechnology, 
Birmingham, Alabama, USA). Samples were incubated for 5 min at 37 °C. After 
immunostaining the cells with fluorescence-labeled antibodies directed against 
CD45 (APC-Cy7), CD11b (FITC), F4/80 (eFluor450), Gr-1 (AF700), and CXCR4 
(APC; (eBioscience), samples were washed, resuspended in 200 µl PBS and 
finally, ICAM-1/CD54-Fc binding to neutrophils was measured via flow cytometry. 
 
3.10 Activation of endothelial cells 
To measure activation of endothelial cells, bEnd.3 microvascular endothelial cells 
were seeded into 12 well plates (200 000 cells/well). The following day, cells were 
stimulated with either Alum crystals (10 µg/ml), TNF (100 ng/ml) as a positive 
control, or PBS as a negative control. After 4 h at 37 °C cells were harvested by 
placing 100 µl of trypsin into each well for 5 min at 37 °C. Next, 1 ml of medium 
was added and the cell suspension was transferred into FACS tubes. After 
centrifugation at 1500 rpm for 5 min, supernatant was discarded and cells were 
resuspended in 100 µl of PBS. Next, cells were labeled with antibodies directed 
against ICAM-1/CD54 (AF488, Biolegend), VCAM-1/CD106 (Pacific blue, 
Biolegend), E-selectin/CD62E (PE, BD Bioscience) and P-selectin/CD62P (APC, 
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Biolegend) for 30 min on ice. After fixing the cells by using lysing solution, samples 
were washed and resuspended in 200 µl PBS. Finally, expression levels of the 
target proteins were measured by flow cytometry. 
The same protocol was used to assess the effects of DAMPs on endothelial cell 
activation. Here, cells were incubated with HMGB1 (1 µg/ml), S100A8/A9 (1 
µg/ml), or MSU crystals (10 µg/ml). 
 
3.11 Immunohistochemistry and confocal microscopy 
3.11.1 Analysis of ICAM-1/CD54 and VCAM-1/CD106 expression in 
cremasteric venules 
In order to investigate the effect of NLRP3 inflammasome activation on the 
expression of ICAM-1/CD54 and VCAM-1/CD106 in cremasteric postcapillary 
venules, mouse cremaster muscles were prepared as described previously (see 
3.6.3) and subsequently detached from the mouse 6 h after intrascrotal (i.s.) 
injection of Alum crystals or saline. In a next step, cremaster muscles were fixed in 
4 % paraformaldehyde for 10 min at RT. After washing the tissue twice in PBS, 
blocking and permeabilization, using 2 % bovine serum albumin (BSA) in PBS with 
0.001 % Triton X-100 for 1.5 h at RT followed. Next, immunostaining of the whole 
mounts with anti-CD31/PECAM AF647 (1:100, Biolegend) and anti-ICAM-1/CD54 
(1:100, rat, Biolegend) or anti-VCAM-1/CD106 (1:100, rat, Biolegend) in blocking 
solution at 4 ° C over night, was performed. After two washing steps in PBS, 
secondary staining with goat anti-rat AF488 antibody (Invitrogen, Carlsbad, 
California, USA) in 2 % BSA in PBS followed, for 2 h at RT. Subsequently, the 
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immunostained tissues were washed in PBS twice more before mounting them in 
PermaFluor (Thermo Fisher Scientific) on glass slides.  
 
3.11.2 Visualizing neutrophils in tumor sections 
Tumors were excised from tumor-bearing mice, embedded in tissue tek (Sakura, 
Alphen am Rhein, Netherlands) and stored at -80 °C. Subsequently, sections were 
cut at 20 µm using a cryostat (Thermo Fisher Scientific) and mounted onto glass 
slides (Thermo Fisher Scientific). After fixing the sections with 4 % formaldehyde 
(Microcos, Garching, Germany) for 10 min at RT, slides were washed in PBS for 
10 min at RT. By incubating the slides in 2 % BSA in PBS with 0.001 % Triton-X-
100 (Sigma Aldrich) for 1.5 h at RT, tumor sections were blocked and 
permeabilized. Next, immunostaining with anti-CD31 AF647 (1:100) and anti-Ly6G 
(1:50), in blocking solution at 4 °C over night, followed. After washing the slides in 
PBS twice, sections were mounted with PermaFluor and slides were stored at 4 
°C.  
 
3.11.2.1 Confocal microscopy and its analysis  
Using a Leica SP8 confocal laser-scanning microscope (Leica) with an oil-
immersion lens (Leica; 40x; NA 1.40), confocal z-stacks (z-spacing 1 μm) of 
postcapillary venules were acquired. In cremasteric tissue whole mounts, the 
fluorescence signal was analyzed using the software Fiji (Schindelin et al., 2012). 
Briefly, confocal microscopy images were merged and z-stacks combined. Using 
the ROI manager software tool, three regions of interest were placed in 
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postcapillary venules of interest as well as in the perivascular space to allow for 
background signal subtraction. 
 
3.12 Assessment of tumor development  
In order to determine the effect of neutrophil depletion on the progression of 
already existing tumors, C3H/HeNCrl as well as BALB/cJ mice received tumor 
cells in a concentration of 2 x 105 cells/20 µl into the outer leg, which allowed easy 
access for continuous measurements of the tumor size on a daily basis using a 
caliper (Hoffmann Group, Munich, Germany). On day 7 after tumor cell injection, 
mice were randomly assigned into two groups. One group received treatment with 
the anti-Ly6G mAb (100 µg) every 48 h, resulting in the depletion of neutrophils. 
The other group received vehicle treatment. After another 7 days of daily 
measurements, mice were sacrificed. 
 
3.13 Cell proliferation assay 
Tumor cells were seeded on a 96-well plate (5000 cells/well). The next day, 
medium was changed and cells were treated with either Alum crystals (10 
µg/100µl), a NLRP3 inflammasome inhibitor (10 µM), a CXCR2 inhibitor, or a 
CXCR4 inhibitor (125 µg/100 µl) for 24 h at 37 °C. Subsequently, medium was 
replaced by serum free media and the MTT Assay was performed according to the 
manufacturer’s protocol (Abcam, Cambridge, UK). First, MTT reagent was added 
for 3 h at 37 °C. In a next step, MTT solvent was also added to the wells. After 
placing the plate on an orbital shaker for 15 min, the absorbance was measured at 
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a wavelength of 590 nm in a microplate reader (Tecan, Männedorf, Switzerland). 
Cell proliferation was determined as the percentage of change in comparison to 
the negative control after background subtraction. 
 
3.13.1 Investigating the effect of tumor-primed neutrophils on cell 
proliferation 
Furthermore, the effect of tumor-primed neutrophils on tumor cell proliferation as 
well as on endothelial cell proliferation was investigated. In order to obtain tumor-
primed neutrophils, tumor-bearing mice were sacrificed two weeks after tumor cell 
injection. Subsequently, neutrophils were isolated either from tumor-bearing mice 
or tumor-free WT mice with the EasySep™ Mouse Neutrophil Enrichment Kit 
(STEMCELL Technologies) according to the manufacturer’s protocol. Briefly, 
whole blood was taken from the vena cava as described previously (see 3.5.1.3) 
and placed into a FACS tube, before incubating it with HetaSep at a ratio of 1:5 for 
5 min at 37 °C. In a next step, 50 µl/ml of rat serum as well as 50 µl/ml of 
neutrophil enrichment cocktail were added to the leukocyte suspension. After 
incubating the samples for 15 min at 4 °C cells were washed in 1 ml PBS and 
centrifuged for 10 min at 300 g. After discarding the supernatant, pellets were 
resuspended in 500 µl of the respective media used for the cells receiving the 
neutrophil treatment. Next, the biotin selection cocktail was added (50 µl/ml) for 
another 15 min at 4 °C. After vortexing the magnetic particles for 30 s, particles 
were added to the samples and incubated for 10 min at 4 °C. Finally, tubes were 
placed into the STEMCELL magnet for 3 min at RT and the samples were poured 
into a new tube. After placing the isolated neutrophils into 6-well plates and 
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incubation at 37 °C over night, supernatants were collected and subsequently 
added onto the cell-cultured tumor or endothelial cells. In addition to the 
supernatants, some wells were also treated with a NE-inhibitor (1mg/ml). After 
incubation for 24 h at 37 °C, the MTT Assay was performed as described above 
(see 3.13). 
 
3.14 Endothelial cell migration 
In order to investigate the effect of tumor-primed neutrophils on endothelial cell 
migration, a scratch assay was performed. For this purpose, tumor-primed 
neutrophils were isolated from the peripheral blood of tumor-bearing mice using 
the EasySep™ Mouse Neutrophil Enrichment Kit, and placed into a 6-well plate 
and cultured at 37 °C over night. The same day, endothelial cells were seeded 
onto 6-well plates (500 000 cells/well). On the following day, a “scratch” was 
created in the confluent endothelial cell monolayer. After washing the cells, 
supernatants from cultured tumor-primed or control neutrophils (isolated from the 
peripheral blood of tumor-free mice) were added to the cultured endothelial cells. 
After 24 h the number of migrated cells into the scratch was assessed and 
normalized to the controls.  
 
3.15 Multiplex immunoassays 
In order to determine cytokine concentrations in SCC VII and 4T1 tumor cell 
supernatants, homogenized tumors, and serum samples, a Bio-Plex chemokine 
assay on a Bio-Plex 200 system, was performed in Kirsten Lauber’s laboratory 
65 
 
(Department of Radiotherapy and Radiation Oncology, LMU München) according 
to the manufacturer’s protocol (Bio-Rad Laboratories, Munich, Germany). 
 
3.16 ELISA 
3.16.1 HMGB1 
In order to measure HMGB1 concentrations in SCC VII and 4T1 cell culture 
supernatants, ELISA analysis was performed in Kirsten Lauber’s laboratory 
(Department of Radiotherapy and Radiation Oncology, LMU München) according 
to the manufacturer’s protocol (IBL International, Hamburg, Germany). 
 
3.16.2 S100A8/A9 
For the investigation of S100A8/A9 concentrations in tumor cell culture 
supernatants, a sandwich ELISA system, developed and performed in Thomas 
Vogl’s laboratory (Department of Immunology, Westfälische Wilhelms-Universität 
Münster), was employed as described previously (Vogl et al., 2014).  
 
3.17 MSU measurements 
Concentrations of uric acid with SCC VII and 4T1 cell culture supernatants were 
determined by Lesca Holdt’s department (Department of Laboratory Medicine, 
LMU München) employing a COBAS 8000 modular analyzer (Roche, Mannheim, 
Germany). 
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3.18 TLR2 and 4 activity assay 
In cooperation with Kirsten Lauber’s laboratory (Department of Radiotherapy and 
Radiation Oncology, LMU München), TLR2 and TLR4 receptor activity after 
stimulation with SCC VII and 4T1 cell culture supernatants was measured as 
described previously (Krombach et al., 2019). 
 
3.19 Statistics 
All data was analyzed using the statistical software GraphPad PRISM (GraphPad 
Software, San Diego, California, USA).The unpaired student’s t-test was used for 
the comparison of two groups. For the estimation of stochastic probability of more 
than two groups, a one-way ANOVA followed by Dunnett’s or Tukey’s posthoc test 
was performed. All data is presented as mean ± standard error of the mean 
(McKaig et al.). Statistical significance was accepted at p-Values < 0.05. 
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Figure 3.1: Quantification of cytokines in SCC VII and 4T1 cell culture supernatants as well 
as solid tumors. Data are shown as heatmaps; n=5 per group. 
 
4 Results 
4.1 Cytokines in supernatants of cultured tumor cells, solid tumors, 
and serum samples 
To explore the expression profiles of cytokines in cultured tumor cells or derived 
tumor tissue raised in mice, a multiplex immunoassay was performed. Our results 
from cell culture supernatants revealed that SCC VII cells release a larger variety 
of cytokines than 4T1 (Fig. 3.1 A). In the derived tumor tissue, however, these 
distinct expression patterns were no longer present, but cytokine expression 
patterns were in general higher (Fig. 3.1 B). 
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Figure 3.2: Quantification of cytokines in serum samples from SCC VII and 4T1 tumor-
bearing mice and healthy controls. Data are shown as heatmaps; n=5 per group. 
Moreover, we analyzed cytokine and chemokine concentrations in serum samples 
from healthy and tumor-bearing mice. No significant differences between these 
experimental groups were observed (Fig. 3.2). 
 
4.2 Neutrophils in the circulation of tumor-bearing mice 
Using multi-channel flow cytometry, we aimed to investigate the number of 
chronologically aged and non-aged neutrophils in the circulation of healthy control 
and tumor-bearing mice by pulse-labeling with BrdU. In 4T1 tumor-bearing mice, a 
significant increase of aged (BrdUnegative) neutrophils and non-aged (BrdUpositive) 
neutrophils in the peripheral blood was observed as compared to healthy control 
mice. In contrast, SCC VII tumor-bearing mice did not show any significant 
changes in the number of circulating neutrophils compared to controls (Fig. 3.3).  
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Figure 3.3: Quantitative analysis of aged and non-aged neutrophils in the circulation of 
healthy control and tumor-bearing mice. Data are presented as mean±SEM; n=3-9 per group; 
*p<0.05; n.s.=not significant. 
 
 
4.3 CXCR4 expression levels on blood neutrophils in tumor-bearing 
mice 
As a measure for neutrophil biological ageing, the expression of the chemokine 
receptor CXCR4 was determined on the surface of circulating neutrophils in 
healthy control and tumor-bearing mice by multi-channel flow cytometry. In both 
SCC VII and 4T1 tumor-carrying mice, neutrophils showed a significant higher 
expression of CXCR4 as compared to neutrophils in control mice. When 
continuously treating tumor-bearing mice with a CXCR2 inhibitor, this increase of 
CXCR4 on neutrophils was significantly reduced (Fig. 3.4). 
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Figure 3.4: Quantification of CXCR4 expression on neutrophils in the circulation of healthy 
controls and tumor-bearing mice treated with a CXCR2 inhibitor or vehicle. Data are 
presented as mean±SEM; n=3-5 per group; *p<0.05; n.s.=not significant. 
 
 
 
 
4.4 The fate of excessively aged neutrophils in tumor-bearing mice 
4.4.1 Accumulation of aged neutrophils in the peritumoral microvasculature  
In a next set of experiments, we investigated the accumulation of adoptively 
transferred, chronologically aged and non-aged neutrophils in the 
microvasculature of the tumor and of its microenvironment. In both SCC VII and 
4T1 tumor-bearing mice significantly more aged neutrophils accumulated in the 
microvasculature of the tumor and the surrounding microenvironment than non-
aged neutrophils (Fig. 3.5). 
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Figure 3.5: Quantification of the accumulation of adoptively transferred, chronologically 
aged and non-aged neutrophils in SCC VII and 4T1 tumors and their microenvironment. Data 
are presented as mean±SEM; n=6-7 per group; *p<0.05. 
 
 
 
4.4.2 Leukocyte subsets in solid SCC VII and 4T1 tumors 
In further experiments, the composition of different leukocyte subsets in solid SCC 
VII and 4T1 tumors was investigated. Employing multi-channel flow cytometry, 
myeloid leukocytes were identified by their expression of CD45 and CD11b. 
Neutrophils were subsequently characterized as Gr-1high and F4/80negative (Fig. 3.6 
A). This analysis revealed that 18.90 % of all leukocytes in SCC VII tumors were 
myeloid leukocytes and 2.74 % were neutrophils. In the 4T1 tumors, 82.15 % were 
myeloid leukocytes and 13.14 % were neutrophils. Using a metabolic pulse-
labeling technique with BrdU, around 80 % of the neutrophilic granulocytes 
present in the tumors, were BrdUnegative aged neutrophils, whereas only 20 % were 
represented by BrdUpositive non-aged neutrophils in both tumor entities (Fig. 3.6 B).  
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Figure 3.6: Quantitative analysis of the composition of different leukocyte subsets in solid 
SCC VII and 4T1 tumors. Schematic overview of the gating strategy (A). Graphical presentation of 
different leukocyte subsets and the percentage of aged and non-aged neutrophils in the tumors 
(B). Data are presented as mean±SEM; n=3-7 per group; *p<0.05. 
 
 
 
Using immunostaining and confocal microscopy, we aimed to further characterize 
the presence of neutrophils within the tumors. Ly-6Gpositive neutrophils were found 
in the tumor microvasculature (identified by CD31positive endothelial cells) as well as 
in the surrounding tumor tissue (Fig. 3.7).  
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Figure 3.7: Representative confocal microscopy images of SCC VII and 4T1 tumor sections. 
Immunostaining with anti-CD31 and anti-Ly6G (scale bar: 25µm). 
 
 
4.5 The recruitment of aged neutrophils 
4.5.1 The release of DAMPs by tumor cells 
In a next series of experiments, we performed measurements of the DAMPs uric 
acid, s100A8/A9, and HMGB1 known to be released by injured or dying cells. We 
did not detect s100A8/A9 (not shown) in SCC VII or in 4T1 tumor cell 
supernatants. In contrast, uric acid release from 4T1 tumor cells was three times 
higher than in SCC VII tumor cells (Fig. 3.8 A). HMGB1 concentrations were very 
low in SCC VII cell culture supernatants, but significantly higher in 4T1 tumor cell 
supernatants as compared to controls (Fig. 3.8 B). 
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Figure 3.8: Quantitative analysis of uric acid and HMGB1 in SCC VII and 4T1 cell culture 
supernatants. Data are presented as mean±SEM; n=5 per group; *p<0.05; n.s.=not significant. 
 
 
4.5.2 The effect of DAMPs on myeloid leukocyte recruitment 
Using a peritonitis assay, we performed quantitative analysis of leukocyte subsets 
recruited upon stimulation with different DAMPs for 6 h. Injection of s100A8/A9 or 
MSU crystals led to a significantly higher extravasation of neutrophils to the 
peritoneal cavity, as compared to unstimulated controls. I.p. injection of HMGB1 
did not reveal any effect on the recruitment of neutrophils in this model. Whereas 
MSU crystals also caused a significant influx of classical monocytes, s100A8/A9 
led to the recruitment of these cells to a much lesser extent. Again, stimulation 
with HMGB1 did not show any effects on the extravasation of classical monocytes. 
The number of non-classical monocytes was not altered by the injection of any 
stimuli (Fig. 3.9).  
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Figure 3.9: Quantification of leukocyte recruitment to the peritoneal cavity after i.p. 
exposure of DAMPs. Analysis of neutrophils (N), classical monocytes (cMOs), and non-classical 
monocytes (ncMOs) recruited to the peritoneal cavity after injection of s100A8/A9, HMGB1, and 
MSU. Data are presented as mean±SEM; n=6-7 per group; *p<0.05; n.s.=not significant. 
 
 
 
 
4.5.3 The effect of tumor-released mediators on TLR2 and TLR4 activity 
Using TLR2 and TLR4 reporter cells and measuring the activity of secreted 
alkaline phosphatase via a plate reader, we investigated whether SCC VII and 4T1 
tumor cells secrete ligands that can potentially activate these receptors. In these 
experiments, treatment with supernatants from both tumor cell lines did not cause 
an increase in the TLR2 and TLR4 reporter activity. As a positive control, 
treatment with the TLR2 agonist FSL-1, a synthetic diacylated lipoprotein, or the 
TLR4 agonist LPS resulted in enhanced TLR2 or TLR4 activity as compared to 
unstimulated controls (Fig. 3.10).  
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Figure 3.11: Quantification of IL-1β in the peritoneal lavage after stimulation with MSU 
crystals. Data are presented as mean±SEM; n=5 per group; *p<0.05. 
 
Figure 3.10: Quantitative analysis of TLR2 and TLR4 activity in reporter cells after 
stimulation with SCC VII and 4T1 cell culture supernatants. Data are presented as mean±SEM; 
n=5 per group; *p<0.05; n.s.=not significant. 
 
 
 
4.5.4 The effect of MSU on inflammasome activation 
As a measure of inflammasome activation, we quantified IL-1β production after i.p. 
injection of MSU. 6 h after the onset of stimulation, IL-1β levels in the peritoneal 
cavity were significantly increased compared to unstimulated controls (Fig. 3.11).  
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4.5.5 The effect of inflammasome activation on myeloid leukocyte 
recruitment 
The peritonitis assay was also employed to investigate the number of extravasated 
neutrophils as well as classical and non-classical monocytes into the peritoneal 
cavity after injection of different inflammasome stimulating substances. Activating 
the NLRP3 inflammasome by injecting Alum crystals led to a significant increase in 
numbers of neutrophils in the peritoneal cavity as compared to saline injected 
mice. Moreover, NLRP3 inflammasome activation by Alum crystals also caused a 
strong recruitment of classical monocytes, however, to a much lesser degree.  
Activation of the AIM2 inflammasome by injecting poly (da:dt), the NLRC4 
inflammasome with FLA-ST, or stimulating the NLRP1 inflammasome with MDP 
did not cause extravasation of neutrophils or classical monocytes. Moreover, the 
number of non-classical monocytes remained unaffected by all treatments (Fig. 
3.12 A). 
Using a pulse labeling strategy with BrdU, we found that the majority (about 60 %) 
of neutrophils recruited upon NLRP3 inflammasome activation with Alum crystals 
were BrdUnegative aged neutrophils. Only about 40 % of the neutrophils were BrdU 
positive non-aged neutrophils (Fig. 3.12 B).  
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Figure 3.12: Quantification of leukocyte recruitment to the peritoneal cavity after injection of 
inflammasome activating substances. Analysis of neutrophils (N), classical monocytes (cMOs) 
and, non-classical monocytes (ncMOs) recruited to the peritoneal cavity after injection of dA:dT, 
Alum crystals, FLA-ST, or MDP. Data are presented as mean±SEM; n=5-8 per group; *p<0.05; 
n.s.=not significant. 
 
 
 
4.5.6 The effect of NLRP3 inflammasome activation on neutrophils 
4.5.6.1 Integrin expression 
In order to analyze the activation of aged and non-aged neutrophils after exposure 
to NLRP3 inflammasome activating Alum crystals, integrin expression on 
neutrophils was measured by multi-channel flow cytometry. We found that CD11a, 
CD11b, and CD49d expression did not significantly differ between unstimulated 
aged and non-aged neutrophils harvested from the peripheral blood of WT mice. 
Similarly, these integrin expression levels remained unaffected by stimulating the 
NLRP3 inflammasome. However, activating neutrophils through TNF led to a 
significant increase of CD11b, but not of CD11a or CD49d in aged and non-aged 
neutrophils (Fig. 3.13). 
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Figure 3.13: Quantification of integrin expression on aged and non-aged neutrophils. 
Analysis of CD11a, CD11b, and CD49d on neutrophils after stimulation with Alum crystals, TNF, or 
vehicle. Data are presented as mean±SEM; n=3-6 per group; *p<0.05; n.s.=not significant. 
 
 
 
4.5.6.2 ICAM-1/CD54-Fc binding 
As a measure of conformational changes of β2 integrins, the capacity of 
neutrophils to bind ICAM-1/CD54-Fc was analyzed. Using multi-channel flow 
cytometry, we found that aged neutrophils tend to bind more ICAM-1/CD54-Fc 
than non-aged neutrophils. Stimulation with Alum crystals did not alter ICAM-
1/CD54-Fc binding in aged or non-aged neutrophils. However, stimulation with 
PMA as a positive control caused a significant increase in ICAM-1/CD54-Fc 
binding in aged neutrophils and also, to a much lesser degree, in non-aged 
neutrophils (Fig. 3.14).  
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Figure 3.14: Quantitative analysis of ICAM-1/CD54-Fc binding properties of aged and non-
aged neutrophils after stimulation with Alum crystals, PMA, or vehicle. Data are presented as 
mean±SEM; n=3-5 per group; *p<0.05; n.s.=not significant. 
 
 
 
4.5.7 The effect of NLRP3 inflammasome activation on endothelial cells 
To investigate endothelial cell activation after NLRP3 inflammasome stimulation, 
ICAM-1/CD54, VCAM-1/CD106, E-selectin/CD62E, and P-selectin/CD62P 
expression was measured using multi-channel flow cytometry. Whereas treatment 
with Alum crystals did not alter the expression of ICAM-1/CD54, VCAM-1/CD106, 
E-selectin/CD62E, or P-selectin/CD62P on cultured microvascular endothelial 
cells, stimulation with TNF resulted in a significantly enhanced expression of these 
molecules as compared to untreated controls (Fig. 3.15). 
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Figure 3.15: Quantification of the activation of endothelial cells after NLRP3 inflammasome 
stimulation. Analysis of ICAM-1/CD54, VCAM-1/CD106, E-selectin/CD62E, and P-selectin/CD62P 
expression levels on endothelial cells after stimulation with Alum crystals or TNF. Data are 
presented as mean±SEM; n=5-6; *p<0.05; n.s.=not significant. 
 
 
 
4.5.8 The effect of DAMPs on endothelial cells 
In addition, the same protocol was used to assess the potential of different DAMPs 
to activate endothelial cells. Stimulation with s100A8/A9, HMGB1, or MSU did not 
change ICAM-1/CD54, VCAM-1/CD106, E-selectin, or P-selectin expression on 
cultured microvascular endothelial cells as compared to untreated controls (Fig. 
3.16). 
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Figure 3.16: Quantification of the activation of endothelial cells after stimulation with 
DAMPs. Analysis of ICAM-1/CD54, VCAM-1/CD106, E-selectin/CD62E, and P-selectin/CD62P 
expression levels after simulation with s100A8/A9, HMGB1, MSU, or TNF. Data are presented as 
mean±SEM; n=3-5 per group; *p<0.05; n.s.=not significant. 
 
 
 
4.5.9 Cytokine release upon NLRP3 inflammasome activation 
Using multiplex ELISA analysis, we also investigated the cytokine release into the 
peritoneal cavity upon NLRP3 inflammasome activation. In comparison to controls, 
stimulation with MSU led to a significant increase in IL-2, IFNу, CXCL2, and CCL3 
release (Fig. 3.17). 
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Figure 3.17: Quantification of cytokines after NLRP3 inflammasome activation. Analysis of 
cytokines in peritoneal lavage after injecting MSU. Data are presented as mean±SEM; n=5; 
*p<0.05. 
 
 
 
4.5.10 ICAM-1/CD54 and VCAM-1/CD106 expression on cremasteric 
endothelial cells after activation of the NLRP3 inflammasome 
To investigate ICAM-1/CD54 and VCAM-1/CD106 expression on cremasteric 
endothelial cells, we employed confocal microscopy analysis of 
immunohistochemically stained cremasteric tissue whole mounts (Fig. 3.18 A). 
Quantitative analysis revealed an increase in ICAM-1/CD54 expression on 
cremasteric endothelial cells after stimulation with Alum crystals for 6 h as 
compared to saline-injected controls whereas VCAM-1/CD106 expression did not 
change (Fig. 3.18 B). 
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Figure 3.18: Analysis of ICAM-1/CD54 and VCAM-1/CD106 expression on cremasteric 
endothelial cells after NLRP3 inflammasome activation. Representative confocal images of 
postcapillary venules in the M. cremaster immunostained with anti-CD31 and anti-CD54 (scale bar: 
25µm) (A). Quantitative analysis of ICAM-1/CD54 expression on cremasteric postcapillary venules 
(B). Data are presented as mean±SEM; n=3 per group; *p<0.05; n.s.=not significant. 
 
 
4.5.11 Myeloid leukocyte trafficking in the cremaster muscle after NLRP3 
inflammasome activation 
4.5.11.1 Analysis after 3 h and 6 h of stimulation 
Employing the musculus cremaster (M. cremaster) assay, the effect of NLRP3 
inflammasome activation on the recruitment of myeloid leukocytes and their 
interaction with the endothelium was investigated. 3 h and 6 h after i.s. injection of 
Alum crystals, in vivo microscopy of postcapillary venules was performed in order 
to assess intravascular rolling and firm adherence of neutrophils and classical 
monocytes. The number of rolling neutrophils and classical monocytes was not 
altered in comparison to saline-injected control mice. Similarly, intravascular firm 
adherence of neutrophils and classical monocytes was not affected 3 h after 
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Figure 3.19: Analysis of IVM on the cremaster muscle after 3 h and 6 h of stimulation with 
Alum crystals. Representative images of postcapillary venules immunostained with anti-Gr-1 and 
anti-CD115 antibodies (scale bar: 25µm) (A). Quantitative analysis of rolling and firmly adherent 
neutrophils, and classical monocytes (cMOs) (B). Data are presented as mean±SEM; n=3-5 per 
group; *p<0.05; n.s.=not significant. 
 
injection of Alum crystals. However, after 6 h of stimulation, a significant increase 
in numbers of firmly adherent neutrophils, and to a much lesser degree, of 
classical monocytes was observed (Fig. 3.19 B).  
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4.5.12 The effect of NLRP3 inflammasome inhibition on neutrophil trafficking 
in tumors 
Using in vivo microscopy, neutrophil trafficking in the tumor and its 
microenvironment was observed. In SCC VII tumors, intravascular rolling was 
significantly increased as compared to tumor-free mice on day 3, but not on day 7 
after tumor cell injection. In contrast, intravascular firm adherence of neutrophils 
significantly increased on day 7 after tumor cell injection as compared to healthy 
animals (Fig. 3.20). In 4T1 tumors, no significant differences were observed in 
numbers of intravascular rolling neutrophils on day 3 or 7 after tumor cell injection, 
whereas intravascular adherence of neutrophils was significantly higher on day 7 
after tumor cell injection as compared to controls (Fig. 3.20). Treatment with an 
NLRP3 inflammasome inhibitor, these increased neutrophil responses in the tumor 
and its microenvironment were completely abolished. 
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Figure 3.20: In vivo microscopy analysis of neutrophil trafficking in the tumor and its 
microenvironment. Analysis of intravascularly rolling and firmly adherent neutrophils on day 3 
(D3) and day 7 (D7) after tumor cell injection in healthy control animals and vehicle- or NLRP3 
inflammasome inhibitor-treated tumor-carrying mice. Data are presented as mean±SEM; n=4-6 per 
group; *p<0.05; n.s.=not significant. 
 
 
 
4.6 The role of aged neutrophils in tumor progression 
4.6.1 The effect of depleting neutrophils in tumor-bearing mice 
In order to investigate the role of neutrophils for tumor progression in SCC VII and 
4T1 carcinoma, mice were rendered neutropenic by antibody-mediated neutrophil 
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Figure 3.21: Analysis of the effects of neutrophil depletion in tumor-bearing mice. 
Quantification of neutrophils in peripheral blood and the tumor as well as of tumor weight in a priori 
(A) or delayed (B) neutrophil-depleted (mAb Ly6G) or isotype control antibody-treated mice. Data 
are presented as mean±SEM; n=3-11 per group; *p<0.05. 
 
depletion. Multi-channel flow cytometry revealed a significantly reduced number of 
neutrophils in the tumors of a priori neutropenic mice as compared to isotype 
control antibody-treated tumor-carrying mice. Moreover, tumor weight was 
significantly lower in neutrophil-depleted tumor-bearing mice (Fig. 3.21 A). 
Noteworthy, delayed neutrophil depletion starting one week after the induction of 
tumor growth did not significantly alter the tumor size as compared to isotype 
control antibody-treated mice (Fig. 3.21 B). 
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Figure 3.22: Quantitative analysis of tumor weight and tumor development after blocking 
the NLRP3 inflammasome, CXCR2, or CXCR4 in tumor-bearing mice. Graphical presentation 
of the tumor development rate and the average tumor weight, depicted by the size of the circle. 
Tumor-bearing mice were either treated with vehicle, an NLRP3 inhibitor, a CXCR4 inhibitor or a 
CXCR2 inhibitor. Data are presented as mean; n=3-15 per group. 
 
4.6.2 The effect of NLRP3, CXCR4, or CXCR2 inhibitors on tumor weight 
and neutrophil infiltration of tumors 
To explore the role of the NLRP3 inflammasome for tumor progression, tumor 
weight and development rates were assessed in mice treated with the highly 
specific NLRP3 inflammasome inhibitor MCC950. Treatment with this inhibitor 
significantly decreased tumor weight and development rates in both SCC VII and 
4T1 tumor-bearing mice.  
To investigate the effects of directly manipulating the ageing process of circulating 
neutrophils, we inhibited the receptors CXCR4 and CXCR2 in tumor-injected mice. 
Whereas blockade of the chemokine receptor CXCR4 lead to a slight increase in 
the tumor weight, antagonizing the chemokine receptor CXCR2 resulted in a 
significant decrease in tumor weight. The tumor development rate however, was 
not significantly altered by these interventions (Fig. 3.22).  
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Figure 3.23: Quantitative analysis of neutrophil infiltration into tumors after blocking the 
NLRP3 inflammasome, CXCR2 and CXCR4 in tumor-bearing mice. Quantitative analysis of 
aged and non-aged neutrophils in tumors of mice treated with a NLRP3 inhibitor (A), a CXCR2 
inhibitor, or a CXCR4 inhibitor (B). Data are presented as mean±SEM; n=3-5 per group; *p<0.05; 
n.s.=not significant. 
 
 
 
In addition, tumor infiltration of aged and non-aged neutrophils was measured in 
these experiments. Blockade of the NLRP3 inflammasome in SCC VII or 4T1 
tumor-bearing mice, led to a significant reduction in the number of neutrophils in 
the tumor (Fig. 3.23 A). In contrast, treatment with inhibitors of CXCR4 or CXCR2, 
however, did not significantly alter the number of neutrophils in the tumors (Fig. 
3.23 B). 
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Figure 3.24: Quantification of tumor cell proliferation after treatment with Alum crystals, a 
NLRP3 inhibitor, a CXCR4 inhibitor, or a CXCR2 inhibitor. Data are presented as mean±SEM; 
n=3-10 per group; n.s.=not significant. 
 
4.6.3 Direct effects on tumor cell proliferation 
Employing a MTT assay, we sought to analyze the role of the NLRP3 
inflammasome for SCC VII or 4T1 tumor cell proliferation. In our experiments, 
neither activating the NLRP3 inflammasome by Alum crystals, nor inhibiting its 
activation by MCC950, led to any significant changes in SCC VII or 4T1 tumor cell 
proliferation as compared to controls. Similarly, blockade of the chemokine 
receptors CXCR2 or CXCR4 did not affect the proliferation of SCC VII or 4T1 cells 
(Fig. 3.24 A+B). 
 
92 
 
Figure 3.25: Quantitative analysis of the expression of N1 and N2 phenotype-associated 
molecules on aged and non-aged neutrophils. Data are presented as mean±SEM; n=3-11 per 
group. 
 
 
 
4.7 The mechanisms underlying tumor growth mediated by aged 
neutrophils  
4.7.1 Expression of N1 and N2 phenotype-associated molecular markers in 
neutrophils recruited by NLRP3 inflammasome activation 
To further investigate the phenotype of neutrophils recruited to the peritoneal 
cavity after NLRP3 inflammasome activation, several surface markers associated 
with a N1 or N2 phenotype of these immune cells were analyzed by multi-channel 
flow cytometry. Aged neutrophils recruited upon NLRP3 inflammasome activation 
showed higher expression levels of NE, MMP9, CCL5, VEGF, CCL3, and Arg-1 on 
their surface as compared to non-aged neutrophils (Fig. 3.25).  
 
93 
 
Figure 3.26: Quantification of tumor cell proliferation after treatment with supernatants from 
tumor-primed neutrophils. Data are presented as mean±SEM; n=4-10 per group; *p<0.05; 
n.s.=not significant. 
 
4.7.2 The effect of tumor-primed neutrophils on tumor cell proliferation 
The effect of neutrophils isolated from the peripheral blood of tumor-bearing mice 
on tumor cell proliferation was investigated by a MTT assay. Both SCC VII and 
4T1 tumor cells showed a significant increase in their proliferation upon incubation 
with supernatants from tumor-primed neutrophils, either isolated from the blood of 
tumor-bearing C3H/HeNCrl mice (SCC VII tumors) or BALB/cJ mice (4T1 tumors) 
as compared to supernatants from neutrophils isolated from tumor-free control 
animals. This increase in tumor cell proliferation was significantly attenuated upon 
administration of a NE inhibitor (Fig. 3.26). 
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Figure 3.27: Quantification of microvascular endothelial cell proliferation after treatment 
with supernatants from tumor-primed neutrophils. Data are presented as mean±SEM; n=5 per 
group; n.s.=not significant. 
 
4.7.3 The effect of tumor-primed neutrophils on microvascular endothelial 
cell proliferation 
In a next set of experiments, we sought to characterize the effect of tumor-primed 
neutrophils on the proliferation of microvascular endothelial cells. Incubation of 
bEnd.3 microvascular endothelial cells with supernatants from tumor-primed 
neutrophils did not significantly alter their proliferation as compared to 
supernatants from control neutrophils harvested from tumor-free mice (Fig. 3.27). 
 
4.7.4 The effect of tumor-primed on the migration of microvascular 
endothelial cells 
To evaluate the effect of tumor-primed neutrophils on the migration of 
microvascular endothelial cells, a scratch assay was performed. Incubation with 
supernatants from neutrophils isolated from tumor-bearing mice did not 
significantly change the number of microvascular endothelial cells migrating into 
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Figure 3.28: Quantification of microvascular endothelial cell migration after treatment with 
supernatants from tumor-primed neutrophils. Data are presented as mean±SEM; n=5-6 per 
group; n.s.=not significant. 
 
the scratch as compared to supernatants from control neutrophils harvested from 
tumor-free mice (Fig. 3.28). 
 
4.7.5 The effect of neutrophil depletion on the microvascular network of 
tumors  
Moreover, we sought to investigate the effect of neutrophils on the architecture of 
the microvasculature of the tumor and its microenvironment. No alterations in the 
overall vessel density as well as in the number of vessel branches or junctions 
were observed in neutrophil-depleted mice, as compared to isotype control 
antibody-treated mice (Fig. 3.29). 
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Figure 3.29: Quantitative analysis of the vessel density, the number of branches, and the 
number of junctions in neutrophil-depleted tumor-bearing mice (mAb Ly6G). Data are 
presented as mean±SEM; n=4-5 per group; n.s.=not significant. 
 
 
4.7.6 The effect of depleting neutrophils on T cell infiltration into tumors 
Finally, we aimed to investigate the effect of neutrophils on the infiltration of CD4+ 
and CD8+ T cells into tumors. Using antibody-mediated depletion of neutrophils in 
SCC VII or 4T1 tumor-bearing mice, no effect on numbers of CD8+ and CD4+ T 
cells present in tumors were observed as compared to isotype control antibody-
treated mice (Fig. 3.30). 
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Figure 3.30: Quantitative analysis of CD4+ or CD8+ T cells in the tumors of neutrophils-
depleted mice (mAb Ly6G). Data are presented as mean±SEM; n=3-5 per group; n.s.=not 
significant. 
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5 Discussion 
5.1 Material and Methods 
In order to validate our findings, we chose to perform the studies in two different 
types of tumors, the SCC VII head and neck cancer and the 4T1 breast cancer. 
These tumors strongly differ in their immunomodulatory properties. Whereas the 
4T1 has previously been described as a highly immunogenic tumor, the SCC VII is 
considered as poorly immunogenic (Lechner et al., 2013). Hence, mechanisms 
found to be relevant for tumor progression in both types of tumors, have greater 
potential of becoming therapeutic targets.  
The model organism we decided to employ for our investigations was the mouse, 
as the mouse immune system is relatively well characterized. Due to our selection 
of tumors, and the origin of our tumor cells, experiments were performed with two 
different mouse strains: C3H/HeNCrl mice for the investigation of SCC VII tumors 
and BALB/cJ mice for analyzing 4T1 tumors. Both models are syngeneic or 
allograft models, meaning we inject tumor cells that were derived from the same 
genetic background as our mouse strain. Other mouse models that are often used 
to investigate potential cancer therapeutics are xenograft models where human 
cancer cells are transplanted into immunocompromised mice. Altering the immune 
system assures that mice do not reject human cell transplants. The syngeneic 
model, however, does not require these alterations in the immune system. Hence, 
when investigating the influence of the immune system on tumorigenesis or 
examining potential immunotherapies the syngeneic model holds clear advantages 
over the xenograft model. 
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In order to investigate tumor progression we decided to not only employ one 
mouse model, but two.  
We incorporated an orthotopic mouse model, in which we injected tumor cells in 
their usual growth site – the floor of the mouth in case of SCC VII or the chest in 
case of 4T1 cells. This approach enables the investigation of tumor progression 
with the influence of a rather natural tumor microenvironment. In addition, the 
orthotopic model allows the growth of tumors that are easy to dissect. Thereby, 
single cell suspensions for the use of multi-channel flow cytometry analysis could 
be obtained.  
Multi-channel flow cytometry is a widely used laser-based method to analyze the 
expression of cell surface and intracellular molecules and characterize cell types 
within a heterogeneous cell population. The method not only measures size and 
volume of the cells, but also the fluorescence intensity by fluorescent-labeled 
antibodies bound to specific cell-associated molecules. However, depending on 
the type of flow cytometer, and the number of lasers and detectors it is equipped 
with, only a specific number of fluorescent labels can be detected, thus limiting the 
amount of molecules one could measure.  
We also used flow cytometry analysis of orthotopically-grown tumors, from mice 
rendered neutropenic. These analyses gave direct insight on the potential impact 
of neutrophils for tumor progression and the recruitment of immune cells to the 
tumor. Moreover, we were able to investigate the effect of different inhibitors or 
antagonists on tumor development, by using this approach. By employing a pulse-
labeling technique with BrdU, we also had the opportunity to gain insight on the 
relative chronological age of neutrophils that were present in the tumor. BrdU is a 
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thymidine analogue, thus enabling the incorporation into DNA during its 
replication. It is a very well-established approach to detect all proliferating cells 
from time of introduction to tissue fixation (Salic & Mitchison, 2008). Hence, 
BrdUpositive cells are non-aged neutrophils and BrdUnegative cells are aged 
neutrophils. To be able to detect the BrdU, a harsh and long treatment of the 
samples is necessary in order to denature DNA and provide access to BrdU. 
These different steps can possible interfere with expression levels of other surface 
molecules, thereby making appropriate negative controls of great importance to 
avoid false results. However, with BrdU allowing the direct detection of cell 
proliferation, it is a very reliable method, creating stable results.  
The second tumor model we employed is a heterotopic model, in which we 
injected tumor cells into the ear. This approach offers a great opportunity of 
consecutive, non-invasive live imaging of leukocyte-tumor interactions. We used 
this model for in vivo imaging of neutrophil-tumor interactions on various days after 
tumor cell injection under baseline conditions, but also after treating tumor-carrying 
mice with different inhibitors or antagonists. Moreover, we also employed this 
model for adoptive cell transfer experiments which allowed the direct comparison 
between interactions of chronologically aged vs chronologically non-aged 
neutrophils in the tumor and its microenvironment. The heterotopic model also 
enabled us to examine the microvascular architecture in tumor-bearing mice and 
in tumor-bearing mice that were rendered neutropenic, thereby analyzing the 
effect of neutrophils on tumor angiogenesis.  
Furthermore, we combined our tumor models with two additional mouse models: 
the M. cremaster assay and the peritonitis assay. By adding these two models, we 
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were able to investigate molecules of interest from the investigated pathways 
outside of the tumor and its microenvironment. The M. cremaster assay is a very 
well established model for live imaging of leukocyte-endothelial interactions after 
the administration of inflammatory stimuli. Due to the thin nature of the muscle, 
imaging the different steps of the leukocyte adhesion cascade is possible. By 
combing this approach with the use of fluorescence-labeled antibodies, we were 
also able to distinguish distinct immune cell populations and even phenotypes. 
With the use of the peritonitis assay, the recruitment of different leukocyte subsets 
to the peritoneal cavity after administrating various stimuli could be investigated. 
By employing multi-channel flow cytometry, we were able to quantify these 
recruited immune cells. However, this should only be considered a “screening 
assay” as there is no possibility to distinguish between the interactions of certain 
immune cells that may have contributed to their infiltration into the peritoneal 
cavity. 
We also employed multi-channel flow cytometry to quantify leukocyte subsets 
within the tumor, characterize the phenotype of neutrophils, and analyze the 
activation status of neutrophils and endothelial cells. When measuring these 
activity states of cells, one disadvantage of this method is that only stronger shifts 
or upregulations of molecules are detectable. Moreover, as some of these 
experiments were performed ex vivo in blood, or in vitro in cell culture 
experiments, one has to be cautious not to activate the immune cells by the 
process of taking the blood or simply pipetting not carefully enough. In addition, as 
cell culture is an isolated approach, the results do not give any indication on the 
influences from other cells. Hence, we also employed immunohistochemistry of 
cremasteric whole mounts as another way of measuring the activation of 
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endothelial cells, for instance. By combing these methods, it is possible to get a 
more comprehensive understanding. 
To gain more detailed insight on the underlying mechanisms of neutrophils in 
tumor progression, we also employed several other in vitro experiments such as a 
cell proliferation assay or a cell migration assay. The MTT cell proliferation assay 
is a commonly used method to investigate the number of viable cells, based on the 
transformation of yellow MTT((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) into blue formazan via mitochondrial enzymes (Sylvester, 2011). Thus, 
we were able to examine the influence of different stimuli and specific molecular 
factors on cell proliferation. In order to explore cell migration we employed a 
scratch assay. By creating a scratch in the monolayer of confluent cells, and 
comparing the cell migration rate into this scratch, the effect of different stimuli 
could be observed. However, it should be noted that in vitro experiments display 
isolated events as there is no environmental influence. Hence, it is best to 
combine these with other in vivo approaches. For instance, a possible approach 
might be to target the molecular factors found in these experiments, in tumor-
bearing mice and measure tumor progression.  
In cooperation with other laboratories, we also employed multiplex analysis and 
ELISA measurements. These methods, especially the multiplex, offer a great 
screening assay for a large variety of cytokines in many different samples.  
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5.2 Results 
Previous studies demonstrated that tumors release a variety of signals that are 
able to influence the tumor microenvironment as well as to manipulate the host’s 
immune response (Coffelt, Wellenstein, & de Visser, 2016; Coussens et al., 2000). 
It has also become apparent that even in earlier stages, cancer is a systemic 
disease rather than a local threat. The potential of tumor-released signals to 
modulate the immune system however, is still not well understood.  
To compare our poorly immunogenic tumor, the SCC VII and the highly 
immunogenic 4T1 tumor, we performed multiplex analysis. Thereby, we 
investigated which signals can be found within cell culture supernatants, solid 
tumors and are released into the systemic circulation. Our data revealed that in 
cell culture supernatants, SCC VII cells release a larger variety of cytokines in 
comparison to 4T1 tumor cells. In contrast, in solid tumors raised from these cells 
in mice, these differences were no longer present. However, 4T1 tumors produced 
higher amounts of cytokines than SCC VII tumors. This might be contributing to 
the higher immunomodulatory properties of 4T1 tumors as compared to SCC VII 
tumors (Lechner et al., 2013). Interestingly, we did not observe any differences 
regarding the concentrations of cytokines in the serum of tumor-bearing mice as 
compared to healthy mice. However, circulating neutrophils might encounter 
higher concentrations of these tumor-derived chemokines only when making their 
way through the tumor and its microenvironment. Moreover, it is possible that the 
tumor-released cytokines are taken up by erythrocytes (Karsten, Breen, & Herbert, 
2018) and presented to circulating neutrophils. Hence, SCC VII and 4T1 tumor 
exhibit common and distinct cytokine expression profiles. 
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To evaluate the numbers of neutrophils present in the systemic circulation of 
tumor-bearing mice, we employed multi-channel flow cytometry. In these 
experiments, we were able to reveal that tumor-bearing mice showed a slight (in 
case of SCC VII) or a strong increase (in case of 4T1) in the number of blood 
neutrophils. This neutrophilia is a previously described phenomenon in various 
types of tumors and has often been described to be associated with a poor clinical 
outcome (Atzpodien & Reitz, 2008; Bellocq et al., 1998; Schmidt et al., 2005).  
A recent publication demonstrated that CXCL2, another ligand for CXCR2, initiates 
the process of neutrophil biological ageing in an autocrine manner (J. M. Adrover 
et al., 2019). Noteworthy, data from the multiplex analysis also revealed that 
concentrations of ligands for CXCR2 were high in tumor cell supernatants as well 
as in tumors itself. We therefore hypothesized that elevated tumor levels of 
CXCR2 ligands in tumor-bearing mice cause circulating neutrophils to age much 
faster than under homeostatic conditions.  
Neutrophils have been shown to acquire higher expression levels of the 
chemokine receptor CXCR4, during their time in the circulation, making CXCR4 an 
ideal marker for aged neutrophils (Eash et al., 2009; Uhl et al., 2016). We found 
that CXCR4 expression was significantly increased on circulating neutrophils in 
tumor-bearing mice as compared to neutrophils in tumor-free control mice. 
Blockade of the ageing-promoting chemokine receptor CXCR2 in tumor-bearing 
mice significantly reduced the expression of CXCR4 on blood neutrophils, 
suggesting that neutrophils in tumor-bearing mice exhibit an excessively aged 
phenotype which is mediated through ligands of CXCR2. Neutrophils in tumor 
patients have been shown to display an extended half-life due to cues released by 
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the tumor microenvironment (Cheretakis, Leung, Sun, Dror, & Glogauer, 2006; 
Sawanobori et al., 2008). With neutrophils spending more time in the circulation, 
this might potentially further support neutrophil ageing.  
 
5.2.1 The fate of excessively ageing neutrophils in cancer 
The time neutrophils spend in the circulation was shown to have a large impact on 
their molecular repertoire, and hence, their function. Ageing neutrophils represent 
highly reactive immune cells that are among the first line of defense when battling 
infections (Uhl et al., 2016). At the same time, this highly reactive phenotype of 
neutrophils can also represent a threat for vascular health under certain conditions 
by promoting microvascular thrombosis (J. M. Adrover et al., 2019). Considering 
that thrombosis has been described as a common complication in tumor patients 
(Sallah, Wan, & Nguyen, 2002), excessively ageing neutrophils in cancer might 
particularly contribute to this phenomenon. The fate of excessively ageing 
neutrophils in cancer, however, is still unclear.  
Employing immunostaining and confocal microscopy on tumor sections, we 
detected neutrophils in SCC VII and 4T1 tumors as well as in the tumor 
microvasculature. The presence of neutrophils in these solid tumors was 
confirmed by multi-channel flow cytometry tumor homogenates. In particular, 
18.90 % of the tumor leukocytes in SCC VII were CD11bpostive myeloid leukocytes, 
and 2.74 % were Ly6Gpositive neutrophils. With 82.15 % of CD11bpositive myeloid 
leukocytes, and 13.14 % Ly6Gpositive neutrophils, levels of these cells in 4T1 tumors 
were a lot higher. Using a pulse labeling technique with BrdU, we further identified 
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that the majority (about 80 %) of neutrophils present in tumors were aged 
neutrophils. 
To confirm these findings, we performed adoptive cell transfer experiments and 
used in vivo microscopy to image interactions between aged and non-aged 
neutrophils in the tumor and its microenvironment. Our data indicate that 
particularly aged neutrophils (isolated from mice exhibiting > 80 % aged 
neutrophils in their circulation upon treatment with blocking anti-P- and E-selectin 
antibodies) accumulate in the microvasculature of the tumor and of its 
microenvironment as compared to non-aged neutrophils isolated from WT mice 
treated with isotype control antibodies (exhibiting < 20 % aged neutrophils). This 
might be explained by previous studies demonstrating increased surface levels of 
integrins such as CD11a, CD11b and CD49d (J. M. Adrover et al., 2016; Uhl et al., 
2016) on aged neutrophils which enable these highly reactive immune cells to 
migrate to sites of inflammation faster. Thus, excessively ageing neutrophils 
preferentially infiltrate malignant tumors. 
 
5.2.2 The recruitment of excessively ageing neutrophils to tumors 
Neutrophil recruitment can be evoked through a variety of stimuli, for instance 
DAMPs released by necrotic or damaged tissue. Previous studies already 
described the release of DAMPs, such as s100A8/A9, HMGB1, or MSU in various 
types of tumors (Hernandez et al., 2016). Thus, we aimed to analyze the amount 
of HMGB1, s100A8/A9, and uric acid in our tumor cells. HMGB1 as well as 
s100A8/A9 concentrations in supernatants from cell-cultured tumor cells were 
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measured using ELISA, whereas uric acid measurements were obtained using a 
COBAS 8000 modular analyzer. 
S100A8/A9 was not detected in the supernatants from our tumor cells, whereas 
HMGB1 was found to be secreted by 4T1 tumor cells and – in very low 
concentrations – by SCC VII tumor cells. Uric acid was detected in supernatants 
from both cell lines. Interestingly, in 4T1 tumor cell supernatants a higher amount 
of uric acid was measured than in SCC VII. Considering that many studies have 
already shown that s100A8/A9 is found in various types of cancer and that it might 
play an important role in tumor progression, (Gebhardt, Németh, Angel, & Hess, 
2006; Salama, Malone, Mihaimeed, & Jones, 2008), our findings seem to be 
surprising at a first glance. However, many positive results of s100A8/A9 might 
originate from phagocytes in tumors, rather from tumor cells themselves, as these 
immune cells have been shown to be a prominent source for s100A8/A9 (Foell, 
Wittkowski, Vogl, & Roth, 2007). In the context of 4T1 tumor cells releasing 
HMGB1 into the supernatant, but not of SCC VII tumor cells, this finding might be 
another hint towards 4T1 being a more immunogenic tumor that displays more 
immunomodulatory potential than SCC VII, through the release of a larger variety 
of DAMPs. Both types of tumors secreting MSU, might contribute to both of the 
tumors immunomodulatory properties, as uric acid is known to be a potent trigger 
for inflammation and immune activation, for instance in active gout (Shi, Mucsi, & 
Ng, 2010). Next, we employed a peritonitis assay in order to investigate the 
potential of DAMPs to induce leukocyte recruitment. Whereas s100A8/A9 as well 
as MSU crystals caused a significant influx of neutrophils and to a lesser degree of 
monocytes, into the peritoneal cavity, HMGB1 did not cause any leukocyte 
recruitment in this assay. In the past, HMGB1 was already thought to be 
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implicated in leukocyte recruitment, however, recent studies revealed pure 
recombinant HMGB1 does not display proinflammatory activity (Bianchi, 2009), 
and that its oxidation status strongly regulates its activity (H. Yang et al., 2012).  
In addition, we also investigated whether the released DAMPs we identified in our 
tumor cell supernatants, have the ability to activate TLR2 or TLR4, the principal 
receptors for HMGB1. Interestingly, treatment with SCC VII and 4T1 cell 
supernatants did not activate either of the receptors, indicating that HMGB1 may 
not be released by our tumor cells in concentrations that result in TLR2 or TLR4 
activation (Yu et al., 2006). This further led us into the conclusion that particularly 
MSU might mediate neutrophil recruitment to tumors.  
DAMPs such as MSU promote inflammatory responses via the activation of 
inflammasomes, an intracellular protein complex facilitating the production of 
inflammatory mediators including IL-1β (Martinon, Pétrilli, Mayor, Tardivel, & 
Tschopp, 2006). Consequently, we hypothesized that activation of inflammasomes 
might regulate the trafficking of excessively ageing neutrophils in cancer to 
malignant tumors. Confirming this hypothesis, administration of MSU crystals led 
to the release of IL-1ß in the peritoneal cavity, indicating inflammasome activity. 
Employing a peritonitis assay, we found that activation of the NLRP3 
inflammasome with Alum crystals, but not of the AIM2 inflammasome with poly 
(da:dt), the NLRC4 inflammasome with FLA-ST, or the NLRP1 inflammasome with 
MDP, led to a significant recruitment of neutrophils and – to a lesser degree of 
classical monocytes to the peritoneal cavity. The majority of neutrophils recruited 
upon NLRP3 inflammasome activation was represented by aged neutrophils as 
indicated by BrdU pulse labeling.  
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To investigate whether activation of the NLRP3 inflammasome causes direct 
effects on neutrophils, integrin expression was analyzed on neutrophils isolated 
from the peripheral blood of WT mice via flow cytometry. No effect of stimulation 
with Alum crystals on the expression levels of CD11a, CD11b, or CD49d on 
neutrophils was observed. Moreover, the ability to bind ICAM-1/CD54-Fc is 
another parameter indicative of conformational changes in β2 integrins, hence, 
neutrophil activation. However, we also did not detect any changes after 
stimulation with Alum crystals. Furthermore, we also aimed to analyze the effects 
of NLRP3 inflammasome activation on endothelial cells by measuring the 
expression levels of ICAM-1/CD54, VCAM-1/CD106, E-selectin, and P-selectin. 
However, stimulation with Alum crystals did not lead to any upregulation of these 
molecules on the surface of cultured microvascular endothelial cells. A recent 
study described that DAMPs do have the potential to activate endothelial cells. In 
this study, however, endothelial cells were not treated by DAMPs directly, but with 
supernatants from tumor cells after radiation (Krombach et al., 2019).  
On the contrary, when we looked at the effect of NLRP3 stimulation with MSU 
crystals on the release of cytokines in an in vivo setting, the peritoneal cavity, we 
detected increased levels of cytokines, likely released from macrophages, such as 
IL-2, IFNу, CXCL2 and CCL3. These findings suggest that it is actually the NLRP3 
inflammasome in macrophages that becomes activated and then facilitates 
neutrophil recruitment by releasing cytokines. This is in line with previous findings 
showing that crystals were phagocytosed by macrophages, incorporated into the 
phagolysosome, and finally lead to lysosomal rupture resulting in activating an 
immune response through releasing cytokines (Hornung et al., 2008). Another 
aspect further confirming this hypothesis is, after injecting Alum crystals into the M. 
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cremaster, cremasteric endothelial cells did show an increase in ICAM-1/CD54, 
whereas cell-cultured microvascular endothelial cells did not show an upregulation 
of this molecule after direct stimulation. In this context, we observed that activation 
of the NLRP3 inflammasome particularly promote intravascular adherence and 
(subsequent) transmigration of neutrophils and – to a lesser degree – of monocyte 
to the perivascular tissue as elicited by in vivo microscopy on the mouse 
cremaster muscle. Hence, in an in vivo setting where macrophages are present, 
endothelial cells become activated through the cytokines released by 
macrophages which in turn facilitates neutrophil recruitment.  
With inflammasomes being such a potent trigger of inflammatory responses, it is 
not too surprising that the involvement of these signaling platforms in various 
pathologies is currently subject to many discussions. Especially, the NLRP3 
inflammasome has been implicated to play a role in tumor progression, however, 
results have been rather contrasting so far. On the one hand, inflammasome loss 
of function has been reported to be associated with enhanced rate and size in 
induced skin carcinogenesis (Gasparoto et al., 2014). On the other hand, 
expression of NLRP3 components and the cytokine IL-1β has been detected in 
oral squamous cell carcinoma tissues, and downregulation of the NLRP3 
expression in oral squamous cell carcinoma tumor cells significantly reduced the 
tumor growth in vivo (H. Wang et al., 2018). 
It should be noted that IL-1ß has recently been shown to stimulate the IL-17-G-
CSF axis (Ueda, Cain, Kuraoka, Kondo, & Kelsoe, 2009), meaning inflammasome 
activation can further support neutrophilia, which in turn is known to support tumor 
progression. Consequently, we aimed to investigate the effect of the NLRP3 
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inflammasome in neutrophil trafficking to malignant tumors. In order to investigate 
this, we established an in vivo ear model that enabled us to continuously image 
neutrophil responses, in the tumor. The number of rolling neutrophils was 
increased in SCC VII but not in 4T1 tumor-bearing mice, whereas significantly 
more neutrophils were adherent in mice injected with both types of tumors. 
Interestingly these increased neutrophil responses were completely abolished 
when we treated tumor-bearing mice with the NLRP3 inflammasome inhibitor 
MCC950. Hence, these data suggest that the NLRP3 inflammasome controls 
neutrophil trafficking to malignant tumors. 
 
5.2.3 The role of excessively ageing neutrophils in tumor progression 
After identifying that excessively ageing neutrophils are recruited to the tumor and 
its microenvironment via the NLRP3 inflammasome, we sought to evaluate the 
role of excessively ageing neutrophils in tumor progression. Consequently, we 
depleted neutrophils in tumor-bearing mice, starting the same day as tumor cell 
injection to ensure the tumor does not have any neutrophils to support tumor 
growth. As expected neutrophils in the blood of tumor-bearing mice as well as in 
malignant tumors were nearly absent. Interestingly, also the tumor weight was 
significantly lower in neutrophil-depleted animals as compared to isotype-treated 
controls. This is in line with previous studies that revealed neutrophil depletion 
results in reduced tumor growth (Jablonska et al., 2010; Jamieson et al., 2012). 
Together with other experimental studies also reporting tumor-supporting 
properties of neutrophils (L. Yang et al., 2004), and the fact that chemotherapy-
induced neutropenia was described to be beneficial for the patient (Di Maio et al., 
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2005), it becomes more and more evident that neutrophils are key players in tumor 
progression. In contrast, when neutrophils were depleted one week after tumor cell 
injection, tumor weight was not affected. Hence, these data suggest that 
neutrophils are in fact important for tumor progression; however, their presence 
seems to be of utter importance for the tumor, especially in the beginning. A recent 
publication revealed that neutrophils from mice with early-stage cancer displayed 
enhanced migratory behavior and showed elevated metabolic activity, in 
comparison to control neutrophils (Patel et al., 2018). This further points towards 
the importance of neutrophils in early tumor disease. 
In order to investigate possible ways to interfere with tumor growth, we employed 
two approaches: we treated tumor-bearing mice with an NLRP3 inhibitor to impair 
neutrophil trafficking or with CXCR4 or CXCR2 inhibitors in order to interfere with 
the neutrophil ageing process. Consequently, tumor weight as well as the tumor 
development rate was assessed. To get a more comprehensive overview, we also 
investigated tumor infiltration of neutrophils, after mice received these different 
treatments by using a flow cytometer. 
Especially inhibiting the NLRP3 inflammasome resulted in a strong decrease in the 
tumor weight and slightly diminished the tumor development rate. Data from the 
multi-channel flow cytometry illustrated that inhibiting the NLRP3 inflammasome 
lead to a significant reduction of neutrophils in the tumor, thus interfering with the 
recruitment of neutrophils. Both of these findings further confirmed that the NLRP3 
inflammasome is a potential therapeutic target with its involvement in neutrophil 
trafficking. 
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Inhibiting CXCR2 also slightly decreased tumor weight, whereas the tumor weight 
in animals treated with a CXCR4 antagonist was slightly increased. Inhibiting 
CXCR2 or CXCR4 however, did not cause any significant alteration in neutrophil 
infiltration into the SCC VII or the 4T1 tumors.  
Since we have shown that CXCR2 binding enhanced the aged phenotype of 
neutrophils, we hypothesized that by inhibiting CXCR2 in tumor-bearing mice, this 
ageing process is interfered with and thereby less reactive tumor-supporting 
neutrophils are generated. As binding of CXCR4 was shown to antagonize the 
ageing process of neutrophils, blocking this receptor leads to a lack of inhibition, 
thereby creating excessively aged, over-reactive neutrophils (J. M. Adrover et al., 
2019). In addition, blocking CXCR4 also inhibits the recruitment of aged 
neutrophils back to the bone marrow, liver, and spleen (Furze & Rankin, 2008), 
hence, leading to an increase of aged neutrophils in the circulation. Thus, the 
tumor has more an even bigger repertoire of excessively ageing neutrophils to 
support its progression. So overall, we conclude that while the NLRP3 
inflammasome is a key regulator in the recruitment of neutrophils, CXCR2 and 
CXCR4 rather regulates the ageing status of neutrophils than the recruitment of 
these immune cells itself. 
CXCR2 has already gotten a lot of attention in the field of cancer therapeutics. In 
contrast to our findings, studies have shown to block neutrophil recruitment via 
antagonizing CXCR2 (Jamieson et al., 2012; G. Wang et al., 2016), although one 
publication demonstrated this recruitment was only transiently reduced and 
rebounded at later time points (Sody et al., 2019). However, other studies also 
confirmed that even though reduction in tumor growth was observed in CXCR2-/- 
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mice, no difference in neutrophil infiltration was observed (Keane, Belperio, Xue, 
Burdick, & Strieter, 2004), thus, further supporting our findings. Hence, the 
chemokine receptor seems to play an important part in shaping the phenotype of 
neutrophils. Accordingly, CXCR2 already is a promising therapeutic target as first 
clinical trial reported positive results in breast cancer patients (Schott et al., 2017).  
 
5.2.4 The mechanisms excessively ageing neutrophils employ to mediate 
tumor growth 
In the final set of experiments, we sought to gain a deeper understanding how 
excessively ageing neutrophils support tumor progression and what mechanisms 
they employ in this context. To this end, expression levels of N1 and N2 
phenotype associated molecules were measured via multi-channel flow cytometry 
on neutrophils recruited by the NLRP3 inflammasome to the peritoneal cavity of 
WT mice. We found that aged neutrophils show higher surface expression levels 
of molecules that were associated with a pro tumorigenic (N2) phenotype of 
neutrophils (Liang & Ferrara, 2016; Powell & Huttenlocher, 2016) including the 
surface expression of NE, MMP-9, VEGF, CCL3, CCL5, and Arg-1 than non-aged 
neutrophils. This is in line with recent observations demonstrating that neutrophils 
progressively degranulate and release their protein content (e.g., NE, MMP-9) 
during ageing in the circulation via a CXCR2-dependent mechanism before being 
ultimately cleared from the bloodstream as ‘exhausted’ neutrophils at the end of 
their life (Adrover et al., 2020). 
By releasing all of these different markers, neutrophils can potentially exhibit 
various functional properties. In our experiments, SCC VII or 4T1 tumor cells 
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exposed to supernatants from tumor-primed, excessively ageing neutrophils, 
tumor cell proliferation was significantly higher as compared to tumor cells 
exposed to supernatants from neutrophils isolated from healthy mice. We also 
added a NE inhibitor when we treated the tumor cells with supernatants from 
tumor-primed neutrophils. This completely diminished the increase in cell 
proliferation. Several studies have already indicated that this cell proliferation 
might be enhanced by secreting NE through downregulating IRS-1, a key regulator 
of PI3K (Houghton et al., 2010). Hence our results confirm the findings from 
previous studies, and clarifying that excessively ageing neutrophils in cancer 
support tumor progression through stimulating tumor cell proliferation by NE. 
Previously, it has been shown that tumor-associated neutrophils have the ability to 
support processes such as angiogenesis (Christoffersson et al., 2012; Massena et 
al., 2015). To this end, we first sought to investigate the effect of tumor-primed 
neutrophils on endothelial cell proliferation and migration. In our experiments, we 
did not observe any effects on endothelial cell proliferation or migration in 
response to supernatants from tumor-primed neutrophils as compared to 
supernatants from control neutrophils. In addition, we also depleted neutrophils in 
tumor-bearing mice and analyzed the microvascular architecture of the tumors. 
We did not observe any differences in the vessel density, the number of branches 
or the number of junctions between neutrophil-depleted and isotype-control 
antibody-treated animals, collectively suggesting that in our models, neutrophils do 
not support tumor angiogenesis. Thus, excessively ageing neutrophils in cancer 
might be a different subpopulation of neutrophils as compared to the previously 
described CD49dhigh VEGFR1high CXCR4high neutrophils that were identified to 
support vascularization of non-vascularized hypoxic tissue (Christoffersson et al., 
116 
 
2012; Massena et al., 2015) or the MMP9high VEGFhigh CXCR4high neutrophils that 
promote angiogenesis in experimental melanoma or fibrosarcoma (Jablonska et 
al., 2010). 
Furthermore, we examined the effect of neutrophils on the presence of T cells in 
tumors, as previous studies have shown that by releasing Arg-1, neutrophils have 
the ability to suppress CD8+ T cell recruitment (Rodriguez et al., 2004; Rotondo et 
al., 2009). However, no difference in the numbers of T cells in the tumor, were 
observed when comparing neutrophil-depleted and isotype-treated tumor mice. 
Thus, in our model neutrophils do not show any effect on T cell recruitment. A 
potential reason for this observation might be that the tumors have other pathways 
substituting for the depleted neutrophils, thereby suppressing CD8+ T cell 
infiltration. For instance, also macrophages have been shown to be sources for 
Arg-1 and to be implicated in interfering with T cell function (Rodriguez et al., 
2003). 
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6 Conclusion 
In conclusion, our data unraveled a previously unknown self-sustaining 
mechanism of malignant tumors that promotes excessive biological ageing of 
circulating neutrophils. To this end, tumor-released ligands of the chemokine 
receptor CXCR2 induce a highly reactive, pro-tumorigenic phenotype in these 
immune cells. Concomitantly, tumor-released uric acid activates the NLRP3 
inflammasome in peritumoral macrophages which, in turn, produce inflammatory 
mediators attracting excessively ageing neutrophils to the neoplastic lesions. Here, 
these immune cells stimulate the proliferation of malignant cells by liberating 
neutrophil elastase, which ultimately promotes tumor growth. Counteracting 
excessive neutrophil ageing in cancer (by CXCR2 inhibitors) and/or trafficking to 
malignant tumors (by NLRP3 inflammasome inhibitors) effectively interfered with 
tumor progression and might therefore provide a promising, already feasible 
strategy in cancer therapy.  
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Figure 4.1: Graphical synopsis. A schematic overview on the here identified mechanisms 
underlying neutrophil trafficking in cancer is shown. 
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Figure 3.2: Quantification of cytokines in serum samples from SCC VII and 4T1 
tumor-bearing mice and healthy controls. 
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Figure 3.3: Quantitative analysis of aged and non-aged neutrophils in the 
circulation of healthy control and tumor-bearing mice. 
Figure 3.4: Quantification of CXCR4 expression on neutrophils in the circulation of 
healthy controls and tumor-bearing mice treated with a CXCR2 inhibitor or vehicle. 
Figure 3.5: Quantification of the accumulation of adoptively transferred, 
chronologically aged and non-aged neutrophils in SCC VII and 4T1 tumors and 
their microenvironment. 
Figure 3.6: Quantitative analysis of the composition of different leukocyte subsets 
in solid SCC VII and 4T1 tumors. 
Figure 3.7: Representative confocal microscopy images of SCC VII and 4T1 tumor 
sections. 
Figure 3.8: Quantitative analysis of uric acid and HMGB1 in SCC VII and 4T1 cell 
culture supernatants. 
Figure 3.9: Quantification of leukocyte recruitment to the peritoneal cavity after i.p. 
exposure of DAMPs. 
Figure 3.10: Quantitative analysis of TLR2 and TLR4 activity in reporter cells after 
stimulation with SCC VII and 4T1 cell culture supernatants. 
Figure 3.11: Quantification of IL-1β in the peritoneal lavage after stimulation with 
MSU crystals. 
Figure 3.12: Quantification of leukocyte recruitment to the peritoneal cavity after 
injection of inflammasome activating substances. 
Figure 3.13: Quantification of integrin expression on aged and non-aged 
neutrophils. 
Figure 3.14: Quantitative analysis of ICAM-1/CD54-Fc binding properties of aged 
and non-aged neutrophils after stimulation with Alum crystals, PMA, or vehicle. 
Figure 3.15: Quantification of the activation of endothelial cells after NLRP3 
inflammasome stimulation. 
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Figure 3.16: Quantification of the activation of endothelial cells after stimulation 
with DAMPs. 
Figure 3.17: Quantification of cytokines after NLRP3 inflammasome activation. 
Figure 3.18: Analysis of ICAM-1/CD54 and VCAM-1/CD106 expression on 
cremasteric endothelial cells after NLRP3 inflammasome activation. 
Figure 3.19: Analysis of IVM on the cremaster muscle after 3 h and 6 h of 
stimulation with Alum crystals. 
Figure 3.20: In vivo microscopy analysis of neutrophil trafficking in the tumor and 
its microenvironment. 
Figure 3.21: Analysis of the effects of neutrophil depletion in tumor-bearing mice. 
Figure 3.22: Quantitative analysis of tumor weight and tumor development after 
blocking the NLRP3 inflammasome, CXCR2, or CXCR4 in tumor-bearing mice. 
Figure 3.23: Quantitative analysis of neutrophil infiltration into tumors after 
blocking the NLRP3 inflammasome, CXCR2 and CXCR4 in tumor-bearing mice. 
Figure 3.24: Quantification of tumor cell proliferation after treatment with Alum 
crystals, a NLRP3 inhibitor, a CXCR4 inhibitor, or a CXCR2 inhibitor. 
Figure 3.25: Quantitative analysis of the expression of N1 and N2 phenotype-
associated molecules on aged and non-aged neutrophils. 
Figure 3.26: Quantification of tumor cell proliferation after treatment with 
supernatants from tumor-primed neutrophils. 
Figure 3.27: Quantification of microvascular endothelial cell proliferation after 
treatment with supernatants from tumor-primed neutrophils. 
Figure 3.28: Quantification of microvascular endothelial cell migration after 
treatment with supernatants from tumor-primed neutrophils. 
Figure 3.29: Quantitative analysis of the vessel density, the number of branches, 
and the number of junctions in neutrophil-depleted tumor-bearing mice. 
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Figure 3.30: Quantitative analysis of CD4+ or CD8+ T cells in the tumors of 
neutrophils-depleted mice. 
Figure 4.1: Graphical synopsis. 
 
Table 1.1: Molecules associated with the N1 and N2 phenotype of neutrophils. 
Table 2.1: Experimental protocol for immunostaining according the different 
surface markers. 
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